

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: January 26, 2005, 12:54:26 ; Search time 191 seconds

(without alignments)  
777.208 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MLSGAYLVRVNERPGQAVW.....SVLQDQWMNPYQNAQQAKEYA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

1825181 seqB, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Maximum Match 0\*

Listing first 45 summaries

Database : UniProt 02;\*

1: uniprot\_sprot:  
2: uniprot\_trembl:  
\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1386	98.1	273	1 GFR4_RAT
2	1075.5	76.1	260	1 GFR4_MOUSE
3	767.5	54.3	299	1 GFR4_HUMAN
4	585.5	41.4	431	1 GFR4_CHICK
5	476.5	33.7	481	2 Q8RTW8
6	476.5	33.7	481	2 AK11261
7	471	33.3	330	2 Q9ZK2
8	469	33.2	358	2 Q9ZK3
9	469	33.2	444	2 Q79X9
10	469	33.2	464	2 Q35977
11	465	32.9	463	1 GFR2_MOUSE
12	465	32.9	463	2 Q92Y3
13	465	32.9	465	1 GFR4_HUMAN
14	464	32.8	331	2 Q725C2
15	464	32.8	463	2 Q35252
16	464	32.8	468	1 GFR1_MOUSE
17	464	32.8	468	2 Q35246
18	463	32.8	461	1 GPR1_CHICK
19	462	32.7	463	2 Q35748
20	462	32.7	464	1 GFR2_HUMAN
21	462	32.7	464	1 AAH41688
22	462	32.7	468	1 GFR4_RAT
23	460.5	32.6	465	1 GFR2_CHICK
24	459	32.5	472	2 Q9BT9
25	459	32.5	472	2 AK11260
26	44.5	30.8	495	2 Q6TC3
27	36.5	25.9	495	2 AAH9464
28	36.5	25.9	397	2 AAH66202
29	364.5	25.8	385	2 Q9R2D
30	364.5	25.8	397	1 GFR3_MOUSE
31	35.7	22.2	Q9QZG2	

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched:

1825181 seqB, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Maximum Match 0\*

Listing first 45 summaries

Database : UniProt 02;\*

1: uniprot\_sprot:  
2: uniprot\_trembl:  
\*

#### SUMMARIES

RESULT 1	
ID	GFR4_RAT
AC	Q9EP12; Q9EP13;
DT	10-OCT-2003 (Rel. 42, Created)
DT	10-OCT-2003 (Rel. 42, Last sequence update)
DB	05-JUL-2004 (Rel. 44, Last annotation update)
DE	GDNF Family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4) (Persiephin receptor)
GN	Name=Gfr4;
OS	Rattus norvegicus (Rat).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Oxfam
RA	SCOTT R., Van Gompel P., Iesage A.S.J., Verhaestelt P., Ibanez C.F., Gordon R.D.,
RA	RT
RT	"Mammalian GFRalpha-4, a divergent member of the GFRalpha family of receptors for Glial cell line-derived neurotrophic factor ligands, is a receptor for the neurotrophic factor persiephin." J. Biol. Chem. 275:39427-39434 (2000).
RL	CC
-I_	-FUNCTION: Receptor for persiephin. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor. May be important in C-cell development and, in the postnatal development of the adrenal medulla.
CC	-I_ SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (Isoform A). Secreted (Isoform B) (Potential).
CC	-I_ALTERNATIVE PRODUCTS: CC
CC	Event=Alternative splicing; Named isoforms=2; Comment=Additional isoforms seem to exist; Name=A'; Isoform=Q9EP12-1; Sequence=Displayed; Name=B';
CC	Isoform=Q9EP12-2; Sequence=VSP_007230; -I_SIMILARITY: Belongs to the GDNFR family.
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to license@isb-sib.ch).
CC	EMBL; AU294475; CAC16420.1; -; EMBL; AU294476; CAC16421.1; -; RGD; G20503; Gfr4; DR; InterPro; IPR002438; GDNF_receptor.
DR	Pfam; PF02351; GDNF; 1.

Aaq89396 homo sapien  
O6609 homo sapien  
Aaq89356 homo sapien  
Q8qkw2 mus musculus  
Q1jv58 ambystoma m  
Q1jv58 homo sapien  
Aaq88565 homo sapien  
Q5xg5 caenorhabditis  
Q8sjeo mus musculus  
AAbl3632 mus musculus  
Q7gde4 anopheles g  
Q8hd2 homo sapien  
Q81001 mus musculus  
Q7pmf9 anopheles g



FT FT a3 and isoform b3).  
 FT FT /Frid=vSP 007228.  
 FT VARSPLIC 191 260 Missing (in isoform a3 and isoform b3).  
 FT SEQUENCE 260 AA; 27990 MW; 2679BBC789838075 CRC64;  
 Query Match 76.1%; Score 1075.5; DB 1; Length 260;  
 Best Local Similarity 89.6%; Pred. No. 2.6e-83;  
 Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;  
 QV 27 GSASSTEENRVERAEEACTADBCQQLSERVYVQCLSLRA--GWRGROSCLVSRCLR 83  
 Db 16 GSASFTDINSKCVPAEACTADBCQQLSERVYVQCLSLRA--GWRGROSCLVSRCLR 83  
 QV 84 RFPIARGPPALTHALLFCCEGPGCAERQRQTAPACAFSGPQLAPPSCLKLPLDRCSRR 143  
 Db 76 RFPIARGPPALTHALLFCCEGPGCAERQRQTAPACAFSGPQLAPPSCLKLPLDRCSRR 135  
 QV 144 CRRPLFLAQASCAPAGSRSRCEBEGGRCRLYAGLTWTFNYLWDNSARVAPWGC 203  
 Db 136 CRRPLFLAQASCAPAGSRSRCEBEGGRCRLYAGLTWTFNYLWDNSARVAPWGC 195  
 QV 204 EAISGNRRBECFAFRKLIFTNPCLDGAIAQFDSSQPSVQDQ 244  
 Db 196 AASGNRRBECFAFRKLIFTNPCLDGAIAQFDSSQPSVQDQ 236

**RESULT 3**

GPR4 HUMAN STANDARD; PRT; 299 AA.

AC 09GZ7; Q9HJ91; Q9H192; 10-OCT-2003 (Rel. 42, Created)

DT 05-JUL-2004 (Rel. 44, Last annotation update)

DE GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4)  
 DE (Persephin receptor).

GN Homo sapiens (Human); Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo. NCBI - Taxid=9606;

RN 1) SEQUENCE FROM N.A. (ISOFORMS GFRALPHA4A; GFRALPHA4B AND GFRALPHA4C), AND GPI-ANCHOR.

RC TISSUE=Thyroid; RX MEDLINE=21153758; PubMed=11116144; DOI=10.1074/jbc.M008219200; RA Lindahl M., Poteryaev D., Yu L., Arunava U., Timusk T., Bongerzone I., RA Aiello A., Pierotti M.A., Airaksinen M.S., Saarma M.; "Human glial cell line-derived neurotrophic factor receptor alpha4 is the receptor for periophelin and is predominantly expressed in normal and malignant thyroid medullary cells."; J. Biol. Chem. 276:9344-9351(2001).

RN 2) SEQUENCE FROM N.A. (ISOFORM GFRALPHA4A).

RA Zhou B., Levinson B., Gitschier J.; Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.

[3] SEQUENCE FROM N.A. MEDLINE=21138749; PubMed=11780052; DOI=10.1038/414065a; RA Deloutas P., Matthews L.H.; Aburat J.L., Burton J., Gilbert J.G.R., Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., RA Beasley O.P., Bird C.P., Blakley S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., Butler A.P., Carter C.C., Carter N.P., Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M., RA Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R., Coulson A., Corrille G.J., Deadman R., Dhani P.D., Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle B., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., Kay M.P., Kimberley A.M., Knight A., Laird G.K., Lawlor S., RA Lehvaeslahti M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA

RA Marsh V.L., Martin S.L., McConnaughey L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.P., Mullikin J.C., Nickeison T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Philimore C.J.C.T., Pratihast S.R., Plumb R.W., Ramsey H., RA Rice C.M., Ross M.T., Scott C.B., Shhra H.K., Showroneen R., Sims S., RA Shue C.D., Smith M.L., Soderlund C., Steward J., Sulston J.E., RA Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., RA Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M., Williams S.A., RA Whitehead S.B., Whittaker P., Willey D.L., Williams L., Williams S.A., RA Wimling L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., RA Rogers J.; "The DNA sequence and comparative analysis of human chromosome 20.", RT RL Nature 414:865-871(2001).

CC CC -1- FUNCTION: Receptor for persephin. Mediates the GDNF-induced autophosphorylation and activation of the RET receptor. May be important in C-cell development and, in the postnatal development of the adrenal medulla.

CC CC -1- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (isoforms Gfralpha4a and Gfralpha4b). Secreted (isoform Gfralpha4c).

CC CC -1- ALTERNATIVE PRODUCTS: Event=Alternative splicing; Named isoforms=3; Comment="Additional isoforms seem to exist;"

CC CC Name=Gfralpha4b; IsoID=Q9GZ7-1; Sequence=VSP\_007223;

CC CC Name=Gfralpha4c; IsoID=Q9GZ7-2; Sequence=VSP\_007223;

CC CC -1- TISSUE SPECIFICITY: Predominantly expressed in the adult thyroid gland. Low levels also found in fetal adrenal and thyroid glands.

CC CC -1- SIMILARITY: Belongs to the GDNFR family.

CC CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation in the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.ebi-sib.ch/announce/> or send an email to license@ebi-sib.ch).

CC DR EMBL; AJ291573; CAC19690.1; DR EMBL; AU291674; CAC19691.1; DR EMBL; AJ291675; CAC19692.1; DR EMBL; AF253118; AAC25925.1; DR EMBL; AU356755; CAC19508.2; DR Genbank; HGNC:13821; GFR4; InterPro; IPR00438; GDNF-receptor; PRAM; PF0231; GDNF; 1. DR PRINTS; PR01316; GDNFRECEPTOR.

KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; receptor; Signal.

FT SIGNAL 1 20 Potential.

FT CHAIN 21 278 GDNF family receptor alpha 4.

FT PROPEP 279 299 Removed in mature form (Potential).

FT CARBOHYD 208 208 N-linked (GlcNAc . .) (Potential).

FT LIPID 278 278 GPI-anchor amidated glycine (Potential).

FT VARSPLIC 132 197 CARAAKAEFWGRKGGLFAHRPPAQSPPGSGLVPSAQ RPRRLPGPGLPARQGRCRAYGVPA->PRLLAQOSCTP APSAPDCGCLDQGRCRAYGVPA (in isoform Gfralpha4a)

FT /Frid=vSP 007224; /Frid=vSP 007223; /CARAAKAEFWGRKGGLFAHRPPAQSPPGSGLVPSAQ RPRRLPGPGLPARQGRCRAYGVPA->PRLLAQOSCTP APSAPDCGCLDQGRCRAYGVPA (in isoform Gfralpha4a)

FT VARSPLIC 183 299 Missing (in isoform Gfralpha4c).

FT SEQUENCE 299 AA; 31669 MW; 84438342FF10801 CRC64;

Query Match 54.3%; Score 767.5; DB 1; Length 299;  
 Best Local Similarity 62.5%; Pred. No. 4.3e-57;

Matches	157;	Conservative	10;	Mismatches	51;	Indels	33;	Gaps	3;
Qy	27	GSASSTEGNRCEAEEACTADEQCOIRSEVAQCLGRAGWRGPSCVRSRCAIRRFF	86	CC	modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to <a href="mailto:license@isb-sib.ch">license@isb-sib.ch</a> ).				
Db	16	GSASSVGGNRCYTDAACTAACRQRSLSERVAQCLGRA--AQGCCPRARCRARRF	72	CC	-----				
Qy	87	ARGPPALTHAILFCGEGPACERRRQTFAFAPACAFSGPQLAPPSCLKPLDRCSRRCR-	145	DR	EMBL; AR045162; AAC16464_1; -				
Db	73	ARGPPALTHAILFCPAGPACERRRQTFFPSCAFSGPGPAPPSCLEPLNCERSVRVC	132	DR	InterPro; IPR00438; GDNF-receptor.				
Qy	146	-----PRIFAFAGSACAGPSGDGEEBEGGRCLRAY	177	DR	pFam; PF0231; GDNF; 1.				
Db	133	ARAANGPWRKGRLGSPAHRAAQSAPPGLSLVHPSAQRPRRLPAGPGRPLPARLGP	192	DR	PRINTS; PRO1316; GDNFRECEPTOR.				
Qy	178	AGL-VGTIVTNTYLDNSARAVAPWGCESAGNRRRECEARRKLTTRNPCLDGAQAFSS	236	KW	glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.				
Db	193	RGVPGTAVIPIVVDNSARVAPWCDGAGSNRRDECAFRLGFLTRNRCLDGAQAFASG	252	FT	SIGNAL 1 19 Potential.				
Qy	237	QPSVHQDQWNP	247	FT	CHAIN 20 403 GDNF family receptor alpha 4.				
Db	253	WPPVLLDQNP	263	FT	PROPEP 404 431 Removed in mature form (potential).				
RESULT 4				FT	CARBOND 180 180 N-linked (GlcNAc. . .) (potential).				
GFR4-CHICK		STANDARD;	PRT;	FT	CARBOND 296 296 N-linked (GlcNAc. . .) (potential).				
AC	093512;			FT	CARBOND 308 308 N-linked (GlcNAc. . .) (potential).				
DT	10-OCT-2003	(Rel. 42, Created)		FT	CARBOND 339 339 N-linked (GlcNAc. . .) (potential).				
DT	05-OCT-2003	(Rel. 42, Last sequence update)		FT	LIPID 403 403 GPI-anchor amidated serine (potential).				
GN	Name=GFR4;	GDNF family receptor alpha 4 precursor (GFR-alpha 4) (GFRalpha4).		SQ	SEQUENCE 431 AA; 47964 MW; 3EDD9453CC4E71B CRC64;				
OS	Gallus gallus	(Chicken)		Query Match	41.4%; Score 585.5; DB 1; Length 431;				
OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			Best Local Similarity	47.4%; Pred. No. 1..8e-41;				
OC	Archosauvia; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;			Matches	110; Conservative 37; Mismatches 72; Indels 13; Gaps 4;				
OX	Gallus			Qy	32 TEGNRCEAEEACTADEQCOIRSEVAQCLGRAGWRGPSCVRSRCAIRRFF				
RN	NCBI_TAXID=9031;			DB	92 ALTHALIFCSCGEGPACERRRQTFFPSCAFSGPQLAPPSCLKPLDRCSRRCRPRLPAP				
RC	SEQUENCE FROM N.A.			Qy	198 BYTHELIFCPCEDTACERRRQTFFPSCAFSGPQLAPPSCLKPLDRCSRRCRPRLPAP				
RX	TISSUE-Embryonic brain;			DB	140 TQVNRCDAAKACCNVDBMCORLTFYVSKEFIRRLLA-RADTNKSKCHALKPFDVRYPP				
RA	MEDLINE:98313402; PubMed=9647690;			Qy	152 QASCAPAPSGSRDGEEGEGRCLRAYAGLVGTUTPNVLDNSARVAPWGCESAGNRE				
RA	Thompson J., Doxakis E., Pinon L.G.P., Strachan P., Buij-Bello A.,			DB	256 QFNCPQSLPASGRDRSYAACLILAYTGIGSPITPTNDNSPSSIAWCTMASGNQE				
RA	Watte S., Buchman V.L.; Davies A.M.;			Qy	212 ECARKLKFTRNPCLDGAQARD-----SSAPSV-LQDQNPYQYQAGQA				
RA	(GFRalpha-4) a new GDNF family receptor.;			DB	316 ECESFLHLFTDNVCLQNAIQAFNGTYINAATAPSISPTTQMYQERNANRA				
RL	[2] Cell. Neurosci. 11:117-126(1998).			RESULT 5	367				
RP	IDENTIFICATION OF LIGAND.			Q98TT8	Q98TT8 PRELIMINARY;				
RX	MEDLINE=98421156; PubMed=9740802;			AC	Q98TT8; PRT; 481 AA.				
RA	Enokido Y., de Savage F., Hongo J.-A., Ninkina N., Rosenthal A.,			DT	01-JUN-2001 (TREMbrel. 17, Created)				
RA	Buchman V.L., Davies A.M.;			DT	01-MAR-2004 (TREMbrel. 17, Last sequence update)				
RT	GFRalpha-4 and the tyrosine kinase Ret form a functional receptor			DE	GDNF family receptor alpha-1b.				
RT	complex for persephin.;			GN	Name=gfralphab;				
RL	Curr. Biol. 8:1019-1022(1998).			OS	Brachydanio rerio (Zebrafish) (Danio rerio).				
CC	-!- FUNCTION: Receptor for persephin. Mediates the GDNF-induced			OC	Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
CC	autophosphorylation and activation of the RET receptor (By			OC	Actinoperygil; Neopterygil; Teleostei; Ostariophysi; Cypriniformes;				
CC	similarity)			OC	Cyprinidae; Danio.				
-!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By				OX	NCBI_TAXID=955;				
similarity).				RN	[1]				
-!- DEVELOPMENTAL STAGE: Expressed in muscle, kidney, brain, stomach and intestine at E6. Levels increase in the brain from E6 to E18, and decrease in muscle and intestine. Levels in the kidney remain constant. From E10, expression also found in heart, lung, skin and liver. Levels in the liver increase dramatically at E18. At E18, highest expression found in kidney and brain. In the embryonic central nervous system, the spinal cord expressed the highest levels. Lower levels found in the medulla oblongata, pons, cerebellum and midbrain, and very low levels in the forebrain.				SEQUENCE FROM N.A.					
This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - use by non-profit institutions as long as its content is in no way				RX	MEDLINE:21135398; PubMed=11237470;				
CC	PubMed:1466438;			RA	Shepherd I.T., Beattie C.E., Raible D.W.;				
CC	DR; GO:004872; F:receptor activity; IEA.			RT	"Functional analysis of zebrafish GDNF."				
CC	DR; InterPro; IPR003438; GDNF-receptor.			RL	Dev. Biol. 231:400-415(2001).				
CC	PF0231; GDNF; 1.			RN	[2]				
CC	PRINTS; PRO1316; GDNFRECEPTOR.			RP	Development 131:241-249(2004).				
CC	EMBL; AA436321; AAU1261_2;			RA	PubMed:1466438;				
CC	DR; GO:004872; F:receptor activity; IEA.			RT	Shepherd I.T., Pietsch J., Elworthy S., Kelsh R.N., Raible D.W.;				
CC	DR; InterPro; IPR003438; GDNF-receptor.			RT	"Roles for GFR[alpha] receptors in zebrafish enteric nervous system development.";				
CC	DR; PF0231; GDNF; 1.			DR	Development 131:241-249(2004).				
CC	PRINTS; PRO1316; GDNFRECEPTOR.			DR	EMBL; AA436321; AAU1261_2;				
CC	Receptor.			RA	Shepherd I.T., Beattie C.E., Raible D.W.;				

SQ	SEQUENCE	PRT	MMW	CRC64;
Query Match	33.7%; Score 476.5; DB 2; Length 481;			
Best Local Similarity	39.9%; Pred. No. 3.6e-32;			
Matches	93; Conservative 39; Mismatches 86; Indels 15; Gaps 4;			
Qy	27 GSASSTEGNRCTVAAEACTADEOCQQLRSEYYAQCLGAGAGWGPQGSCVRSCRALRRP	0922A2	PRELIMINARY;	PRT; 330 AA.
Db	152 GEAFTKONNCNNAAKACNLNTCKKRSLSYI5PCTSRS--TTEVNKRKCKHAKLQFF	0922A2	PRELIMINARY;	PRT; 330 AA.
Qy	87 ARGGPPALTHALIFFCGC---EGPACERROTAPACAPSGPQLAPPSCILKPLDRERSRR	01-MAY-1999 (TREMBLrel. 10, Created)		
Db	210 DKVPPKHYSYGMFLFCSCPDSGHACSERROTIVPACSYEDKE--KPNCLISQASCNHYI	01-MAY-1999 (TREMBLrel. 10, Last sequence update)		
Qy	144 CIPRLFARQASCAPAPSRRDGCPEEGPRCIRAYGLVGTWTPTNLDNSARAVAPGCC	01-JUN-2003 (TREMBLrel. 24, Last annotation update)		
Db	268 CRSRLADFLTNCOPEARSI5GCLTNYADLAYSGLIGTWTPTNLDNSARAVAPGCC	Gial cell line derived neurotrophic factor family receptor alpha		
Qy	204 EASGNRRECEAFARKLFLTRNPCLDGATQAFDS-----OPSVLQDQWNPY 248	2c. Name-Gfra2;		
Db	328 SNSGNGKAECDKTEFFTINRNCLRNAIQAFGNGTDVGWQPQPPIMSTPAQY 380	GN OS Mus musculus (Mouse).		
<b>RESULT 6</b>				
AAK1261				
ID AAK1261	PRELIMINARY; PRT; 481 AA.			
AC AAK1261;				
DT 02-MAR-2004 (TREMBLrel. 27, Last sequence update)				
DT 02-MAR-2004 (TREMBLrel. 27, Last annotation update)				
DB GDNF family receptor alpha-1b.				
GN GFRALPHA1B.				
OS Brachydanio rerio (Zebrafish) (Danio rerio).				
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;				
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;				
OC Cyprinidae; Danio.				
OX NCBI_TAXID-7955;				
RN [1]				
RP SEQUENCE FROM N.A.				
RX MEDLINE:21135398; PubMed:11237470;				
RA Shepherd J.T., Beattie C.E., Raible D.W.; Dev. Biol. 231:420-435(2001).				
RT "Functional analysis of zebrafish GDNF."				
RL [2]				
RN SEQUENCE FROM N.A.				
RP PubMed-14680438;				
RA Shepherd J.T., Pietsch J., Elworthy S., Kelsh R.N., Raible D.W.; RT "Roles for GFR[alpha]1 receptors in zebrafish enteric nervous system development." Development 131:241-249(2004);				
RL EMBL: AY436321; AAK1261.2; -.				
KW Receptor.				
SQ SEQUENCE	330 AA; 53639 MW; 478917653049CB23 CRC64;			
<b>Query Match</b>				
Best Local Similarity	33.3%; Score 471; DB 2; Length 330;			
Matches	91; Conservative 31; Mismatches 86; Indels 6; Gaps 3;			
Qy	22 LGCGRGSSASTGNRCTVAAEACTADEOCQQLRSEYYAQCLGAGAGWGPQGSCVRSCRALRRP	13 LGCGADPVSAESNHCDAAKACNLNDCKKRSVSYICIREIS--PTERGNRKCHKA	70	
Db	82 LRGFFAGPPLTHALIFFCGEGPACERROTAPACAFSGPQLAPPSCILKPLDRERS	71 LKOFFDPDRUPSEVTYRMIFCSCODQACKERRORTILPSCSYDEKE--KPNCLDLRSLRD	141	
Qy	142 RCRPRFAQASCAPAPSRRDGCPEEGPRCIRAYGLVGTWTPTNLDN--VSARAVP	71 LKOFFDPDRUPSEVTYRMIFCSCODQACKERRORTILPSCSYDEKE--KPNCLDLRSLRD	188	
Db	129 HLCRSRLADFHANCRAKYRTISCPANDYQAGLSYAGMICPDMDTENYVDNSPTGTWSP	71 LKOFFDPDRUPSEVTYRMIFCSCODQACKERRORTILPSCSYDEKE--KPNCLDLRSLRD	222	
Qy	200 WGCEASGNRRECEAFARKLFLTRNPCLDGATQAF	189 WCNCRGSGNMEMEBCEKELDKFTENPCRNLAQAF	233	
Db	189 WCNCRGSGNMEMEBCEKELDKFTENPCRNLAQAF	222		
<b>RESULT 8</b>				
Q922A3				
ID Q922A3	PRELIMINARY; PRT; 358 AA.			
AC Q922A3;				
DT 01-MAY-1999 (TREMBLrel. 10, Created)				
DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)				
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)				
DE Gial cell line derived neurotrophic factor family receptor alpha				
DB 2b.				
GN Name-Gfra2;				
OS Mus musculus (Mouse).				
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi;				
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Murida; Murinae; Mus				
OX NCBI_TAXID-10090;				
RN [1]				
RP SEQUENCE FROM N.A.				
RA Wong Y.W., Too H.P.;				
RT "Identification of mammalian GFRalpha-2 splice isoforms.";				
RL EMBL: AF079107; AAC02464.1; -.				
Db	328 SNSGNGKAECDKTEFFTINRNCLRNAIQAFGNGTDVGWQPQPPIMSTPAQY	380		



DB	329	GNNEBECFKELRDETFENPCLNATQAF	355
RESULT 11			
GFR2_MOUSE	STANDARD;	PRT;	463 AA.
ID GFR2_MOUSE			
AC 008842;			
DT 01-NOV-1997 (Rel. 35, Created)			
DT 01-NOV-1997 (Rel. 35, Last sequence update)			
DT 05-JUL-2004 (Rel. 44, Last annotation update)			
DE GDNF family receptor alpha 2 precursor (GFR-alpha 2) (Neurturin receptor alpha) (NTNR-alpha) (TGF-beta related neurotrophic factor receptor 2) (GDNF receptor beta) (GDNFR-beta).			
DE Name=Gfr2; Synonyms=Gdnfrb, Trnr2;			
GS Mus musculus (Mouse);			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Buteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus; NCBI_TaxID=10090;			
RN [1]			
RP SBQUENCE FROM N.A. (ISOFORMS 1 AND 2).			
RX MEDLINE=972591; PubMed=9182803;			
RA Balon R.H., Tansey M.G., Golden J.P., Creedon D.J., Heuckeroth R.O., Keck C.L., Zimonjic D.B., Popescu N.C., Johnson E.M. Jr., Milbrandt J., Tremble J., Johnson D., Johnson E.M. Jr., Johnson E.M. Jr., Neuron 18:793-802(1997).			
RT "Trnr2, a novel receptor that mediates neurturin and GDNF signaling through Ret.";			
RT Neuron 18:793-802(1997).			
-I- FUNCTION: Receptor for neurturin. Mediates the NTNR-induced autophosphorylation and activation of the RET receptor. Also able to mediate GDNF signaling through the RET tyrosine kinase receptor.			
-I- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor (By similarity).			
-I- ALTERNATIVE PRODUCTS:			
CC Event=Alternative splicing; Named isoforms=2;			
CC Name=1; Synonyms=long; IsoId=008842-1; Sequence=Displayed;			
CC Name=2; Synonyms=short; IsoId=008842-2; Sequence=VSP_001662;			
-I- TISSUE SPECIFICITY: Neurons of the superior cervical and dorsal root ganglia and adult brain and testis. Low level in the spleen and in the adrenal gland.			
-I- SIMILARITY: Belongs to the GDNFR family.			
CC			
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <a href="http://www.isb-sib.ch/announce/">http://www.isb-sib.ch/announce/</a> or send an email to license@isb-sib.ch).			
RN [1]			
RP SEQUENCE FROM N.A.			
RX MEDLINE=22712886; PubMed=12829325;			
RA Too H.P.;			
RT "real time PCR quantification of GFRalpha-2 alternatively spliced isoforms in murine brain and peripheral tissue.;"			
RL Brain Res. Mol. Brain Res. 114:146-153(2003).			
RN [2]			
RP SEQUENCE FROM N.A.			
RC STRAIN=C57BL;			
RA Wong Y.W., Too H.P.;			
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.			
DR AF398116; AAK9483.1; -;			
DR AF398111; AAK9483.1; JOINED.			
DR AF398112; AAK9483.1; JOINED.			
DR AF398114; AAK9483.1; JOINED.			
DR AF398115; AAK9483.1; JOINED.			
DR AF398113; AAK9483.1; JOINED.			
DR GO; GO:0004872; F:receptor activity; IEA.			
DR InterPro; IPR05438; GDNF_receptor.			
DR InterPro; IPR003504; GDNF_receptorA2.			
DR Pfam; PF02551; GDNF; 1.			
DR PRINTS; PR01316; GDNFRECEPTOR.			
DR EMBL; AF002701; AAC5548.1; -.			
DR MGI; MGI:1195462; Gfr2.			
DR InterPro; IPR00438; GDNF_receptor.			
DR Pfam; PF02551; GDNF; 1.			
DR PRINTS; PR01316; GDNFRECEPTOR.			
KW Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane; Receptor; Signal.			
FT SIGNAL 21 Potential.			
FT CHAIN 22 443 GPIB family receptor alpha 2.			
FT PROPEP 444 463 Removed in mature form (Potential).			
FT CARBOHD 52 52 N-Linked (GlcNAc. .) (Potential).			
FT CARBOHD 357 357 N-Linked (GlcNAc. .) (Potential).			
FT LIPID 413 413 N-Linked (GlcNAc. .) (Potential).			
FT VARSPIC 443 443 GPI-anchor amidated serine (Potential).			
FT 146 146 Missing (in isoform 2). /Pfam=VSP_001662.			
SQ 51598 MW; 42FAA1EP59975E2C CRC64;			
Query Match Best Local Similarity 32.9%; Score 465; DB 2; Length 463; Matches 88; Conservative 32; Mismatches 79; Indels 6; Gaps 3;			
QY 31 STECNRCVAAEACTADBCQQURSERVAQCGLGRAGWRGPSCVRSSRRARRPARGP 90			
Db 155 SAKSNHCLDAKACNLNDCKKRSYISIREIS--PTECNRKCKAHLQRPRV 212			
OY 91 PALTHALIFCGEGPACERROTAPACAFSGPOLAPPSCPKPLDRCRERSHRCPRLFA 150			
Db 213 SETTYRMFLPCSCQDQACERRQTLPLSCSYEDKE--KPNCLDLRLSLCRTDILCRSLRD 270			
OY 151 FOSCAPAPGPGCPCGGPCTAVAGIVWTNTYD--VSARVAPGGCRSGN 208			



DR	EMBL; AR058999; AACI4431.1; -.	DR	Homo sapiens (Human).
DR	EMBL; AR058991; AACI4431.1; JOINED.	OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
DR	EMBL; AR058992; AACI4431.1; JOINED.	OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
DR	EMBL; AR058993; AACI4431.1; JOINED.	NCBI_TaxID=9606;	[1]
DR	EMBL; AR058994; AACI4431.1; JOINED.	RN	SEQUENCE FROM N.A.
DR	EMBL; AR058995; AACI4431.1; JOINED.	RA	Young L.P., Too H.P.; Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
DR	EMBL; AR058997; AACI4431.1; JOINED.	RL	EMBL; AV326396; AAB8838.1; -.
DR	EMBL; AR058998; AACI4431.1; JOINED.	DR	GO; GO:0014636; F:receptor activity; IBA.
DR	EMBL; U95847; AAB7181.1; -.	DR	InterPro; IPR03428; GDNF_receptor.
DR	EMBL; BC014961; AACI44962.1; -.	DR	Pfam; PF02351; GDNF; 1.
DR	EMBL; HGNC:243; GFRA1.	KW	Receptor.
DR	MIM: 601496; -.	SQ	SEQUENCE: 331 AA; 36470 MW; 10BCEA5492E2393C CRC64;
DR	GO; GO:0019898; C:extrinsic to membrane; NAS.	Query Match	32.8%; Score 464; DB 2; Length 331;
DR	GO; GO:0017165; P:cell surface receptor linked signal transdu. . . ; NAS.	Best Local Similarity	38.7%; Pred. No. 2.9e-31;
DR	InterPro; IPR03438; Gdnf_receptor.	Matches	92; Conservative 38; Mismatches 102; Indels 6; Gaps 3;
PR	PRINTS; PRO116; GDNFRECEPTOR.	QY	22 LGCGGSASSTEGURCVEEAECTADBCQCOLRSYVAOCIGRAGWRGPSCVRSCRA 81
KW	Alternative splicing; Glycoprotein; GPI-anchor; Lipoprotein; Membrane;	Db	13 LGTGADPVSAKSNSHCLDAKACNLUANDNCKKLRSYISICNREIS-PTRCRNRKCKHA 70
PR	GO; GO:0004872; F:receptor activity; NAS.	QY	82 LRRFPIRGPAFHALLIFGCGCEPGPACAERRRQTPAPACASGPOLAPPSCIKPLDRCERS 141
FT	SIGNAL 1 24 Potential	Db	71 LRQFDFDRVPSSBYTRMLFCSCQDCAACERRQTLIFPSYCSEDEKE--KPNCDLRGVCRTD 128
FT	CHAIN 25 429	QY	142 RCRCPRLFARQASCPAPSSRDGGPGEERGRCLRAYLAGVLYGTWVTPNYLN-VSARVAP 199
PROPEP	430 465	Db	129 HLCRSRLRADPHANCRASTRAYCOTVTSCPADNYQACLESYAGMIGRDFMTNPYVSSPTGIVSP 188
FT	DOMAIN 362 369	QY	200 WCGEASGNRREECAFRLKFTPMLCDGIAQAFQSSQPSSVLQDQNPYQAGAQKVE 257
FT	CARBHYD 59 59	Db	189 WCGSGSGNMEECFKFLRDPTEPLRNIAQAFONGTDWNVSPKGPSFQTAQPRVE 246
FT	CARBHYD 347 347	QY	/FT1=VAR 012489.
FT	CARBHYD 406 406	Db	/FT1=VAR 012489.
FT	LIPID 429 429	QY	/FT1=VAR 012489.
FT	VARSPLIC 144 144	Db	/FT1=VAR 012489.
FT	VARIANT 85 85	QY	/FT1=VAR 012489.
FT	VARIANT 366 366	Db	/FT1=VAR 012489.
FT	VARIANT 371 371	QY	L->R (may be involved in congenital central hypoventilation syndrome).
FT	CONFFLICT 245 245	Db	/FT1=VAR 012489.
FT	CONFLICT 358 358	QY	Missing (in Ref. 1).
FT	SEQUENCE 465 AA; 51455 MW; 91A55D06A677/BD CRC64;	Db	F->P (in Ref. 1).
QY	Query Match 33 EGNRGEVAAEACTADBCQCOLRSYVAOCIGRAGWRGPSCVRSCRA 92	RESULT 15	035252
QY	Best Local Similarity 41.9%; Pred. No. 3.3e-31;	ID	035252 PRELIMINARY; PRT; 463 AA.
QY	Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;	AC	035252; DR
Db	150 KGNNDAAKAGCAGNULDICKYKRSVATPCTISV--SNDVCRNRRKCHKAQFFDKUPAK 206	DT	01-JAN-1998 (TREMBLrel. 05, Created)
Db	93 LTHALILFCGCGPACERRRQTFAAACAFSGPQLAPPSCIKPLDRCRSRSCRPRLFQ 152	DT	01-JAN-1998 (TREMBLrel. 05, Last sequence update)
Db	207 HSYGMLFCSCRDIACATTERRQQTIVPCSYE--ERBKPNCLNLQDSCKTNYCRSLRADF 264	DT	01-JUN-2003 (TREMBLrel. 24, Last annotation update)
Qy	153 ASCARAPGSRDGGPCEGGPRCLRAYLAGVLYGTWVTPYLDSVARYAPWGCGEASGNRREE 212	DR	GDNF receptor beta.
Qy	265 TNCOFPESRSVSSLCCYNAQCLLASSGLIGTWVTPYIDSSLSVAPWCODCSNSGNDLE 324	DR	Name=Giraf; Synonyms=GDNFR-beta;
Qy	213 CEAFRKLIFTNPCLDGAIAQFDSSCOPSVLQDQWNP 247	DR	Mus musculus (Mouse);
Db	325 CLKFLNFFKONTCLKAIAQFGNGSDVTV--WQP 356	DR	Eukaryota; Metazoa;
RESULT 14	Q7Z5C2	PR	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. [1]
Q7Z5C2	ID	PRELIMINARY; PRT; 331 AA.	
Q7Z5C2	Q7Z5C2	SEQUENCE FROM N.A.	
Q7Z5C2	Q7Z5C2	PR	
Q7Z5C2	Q7Z5C2	STRAIN=C57;	
Q7Z5C2	Q7Z5C2	MEDLINE=98252741; PubMed=9592044;	
Q7Z5C2	Q7Z5C2	Dey B.K., Wong Y.W., Too H.P.; Cloning of a novel murine isoform of the glial cell line-derived neurotrophic factor receptor.;	
Q7Z5C2	Q7Z5C2	RT "Cloning of a novel murine isoform of the glial cell line-derived neurotrophic factor receptor.;"	
Q7Z5C2	Q7Z5C2	RT NeuroReport 9:37-42 (1998).	
Q7Z5C2	Q7Z5C2	RL EMBL; AP015172; AAB86600.1; -.	
Q7Z5C2	Q7Z5C2	DR MGI; MGI:1100842; Giraf.	
Q7Z5C2	Q7Z5C2	DR GO; GO:0014636; F:receptor activity; IBA.	
Q7Z5C2	Q7Z5C2	DR InterPro; IPR03438; GDNF receptor.	
Q7Z5C2	Q7Z5C2	DR InterPro; IPR03503; GDNF receptor.	
Q7Z5C2	Q7Z5C2	DR PRINTS; PR01317; GDNF_PALPHA1.	
Q7Z5C2	Q7Z5C2	DR PRINTS; PR01316; GDNFRECEPTOR.	
Q7Z5C2	Q7Z5C2	DR Receptor.	
Q7Z5C2	Q7Z5C2	KW SEQUENCE: 463 AA; 51134 MW; BAF2A152E262C037 CRC64;	
Q7Z5C2	Q7Z5C2	Query Match 32.8%; Score 464; DB 2; Length 463;	
Q7Z5C2	Q7Z5C2	Best Local Similarity 41.2%; Pred. No. 4e-31;	
Q7Z5C2	Q7Z5C2	Matches 89; Conservative 32; Mismatches 87; Indels 8; Gaps 3;	
Q7Z5C2	Q7Z5C2	Alpha2c.	

Db 144 SKGNNCNIDAAKACCNLDTCCKYRSAVTPCTS--MSNEVCNRKCKHALRPPFDKPA 200  
 Qy 92 ALTHAALPCGGEGPAGCAERRQTAFACATSGPQLAPPSCIKPLDRCECSRRCPRPFAP 151  
 :: :| :|| | :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|  
 Db 201 KHSYGHFLFCSDRVDACATTERRQTTIVFVCSTE-ERERPNCLNLQDSCSKINYCIRSRAADF 258  
 Qy 152 QASCAPAPGSRDGGCPEGGERCLRAYAGIYGTVTPNYLDNSARVAPWCGEASGRRE 211  
 :: :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|  
 Db 259 FTNCOPESRSVSNSNCLKENYADCLLAYSGLIGTWTMPNYDSSLSVAIWCDCSNSGNDE 318  
 Qy 212 ECEAFKLFLTRNPCLGATOAFDSSQPSLQDQWNP 247  
 :: :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :| :|  
 Db 319 DCLKENFFKDNTCLKNAQAFGNGSDVIM--WQP 351

Search completed: January 26, 2005, 13:15:40  
Job time : 193 secs

GenCore version 5.1.6  
 Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model  
 Run on: January 26, 2005, 13:09:51 ; Search time 40 Seconds  
 (without alignment(s))  
 427.751 Million cell updates/sec

Title:	US-10-019-337E-9
Perfect Score:	1413
Sequence:	MISGAYLVRVNRVPGQAVW. .... SVIADQDMNPYQYNAQQAKVEA 258
Scoring table:	BLOSUM62
Gapop:	10.0 , Gapext 0.5
Searched:	478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0  
 Maximum DB seq length: 200000000  
 Minimum Match 0%  
 Maximum Match 100%  
 Listing first 45 summaries

Database : Issued Patents AA:\*

- 1: /cgn2\_5/prodata/1/iaa/5A\_COMB.pep:\*
- 2: /cgn2\_6/prodata/1/iaa/5B\_COMB.pep:\*
- 3: /cgn2\_6/prodata/1/iaa/6A\_COMB.pep:\*
- 4: /cgn2\_6/prodata/1/iaa/6B\_COMB.pep:\*
- 5: /cgn2\_6/prodata/1/iaa/PCTRUS\_COMB.pep:\*
- 6: /cgn2\_6/prodata/1/iaa/backfile1.epl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	515	36.4	132	3 US-09-724-864-65	Sequence 65, Appl
2	469	33.2	45	4 US-09-861-990-11	Sequence 11, Appl
3	469	33.2	45	3 US-08-057-053-6	Sequence 6, Appl
4	469	33.2	464	3 US-09-887-605-6	Sequence 6, Appl
5	469	33.2	464	3 US-08-002-805D-6	Sequence 6, Appl
6	469	33.2	464	3 US-08-861-930-2	Sequence 2, Appl
7	469	33.2	464	4 US-09-988-316C-6	Sequence 6, Appl
8	469	33.2	664	3 US-08-957-053-18	Sequence 16, Appl
9	469	33.2	664	3 US-09-887-605-18	Sequence 18, Appl
10	469	33.2	664	3 US-08-802-805D-13	Sequence 18, Appl
11	469	33.2	664	4 US-09-388-316C-13	Sequence 18, Appl
12	465	32.9	346	4 US-09-887-906-9	Sequence 9, Appl
13	465	32.9	460	3 US-08-802-805D-22	Sequence 11, Appl
14	465	32.9	460	4 US-09-187-906-11	Sequence 10, Appl
15	465	32.9	463	4 US-08-337-199A-10	Sequence 12, Appl
16	465	32.9	463	4 US-08-837-199A-12	Sequence 1, Appl
17	465	32.9	465	4 US-08-037-199A-2	Sequence 6, Appl
18	465	32.9	465	4 US-08-837-199A-6	Sequence 8, Appl
19	465	32.9	465	4 US-08-861-990-8	Sequence 22, Appl
20	465	32.9	465	4 US-09-388-316C-22	Sequence 3, Appl
21	462	32.7	465	3 US-08-857-053-3	Sequence 3, Appl
22	462	32.7	464	3 US-09-987-605-3	Sequence 3, Appl
23	462	32.7	464	3 US-08-002-805D-3	Sequence 3, Appl
24	462	32.7	464	4 US-09-887-906-13	Sequence 13, Appl
25	462	32.7	464	4 US-08-861-990-9	Sequence 9, Appl
26	462	32.7	464	4 US-09-388-316C-3	Sequence 3, Appl
27	462	32.7	464	3 US-08-802-805D-24	Sequence 21, Appl

RESULTS

RESULT 1  
 US-09-724-864-65  
 Sequence 65, Application US/09724864  
 Patent No. 6380362  
 GENERAL INFORMATION:  
 APPLICANT: Watson, James D.  
 TITLE OF INVENTION: Polynucleotides, polypeptides expressed by the polyribosomes and methods for their use.  
 FILE REFERENCE: 11000-1050U1  
 CURRENT APPLICATION NUMBER: US/09/724-864  
 CURRENT FILING DATE: 2000-11-28  
 PRIOR APPLICATION NUMBER: U.S. No. 6380362 60/171,678  
 PRIOR FILING DATE: 1999-12-23  
 NUMBER OF SEQ ID NOS: 72  
 SOFTWARE: FastSEQ for Windows Version 4.0  
 SEQ ID NO: 65  
 LENGTH: 132  
 TYPE: PRT  
 ORGANISM: Mouse

RESULT 2  
 US-09-724-864-65  
 Query Match 36.4%; Score 515; DB 3; Length 132;  
 Basic Local Similarity 94.0%; Pred. No. 2.4e-40;  
 Matches 94; Conservative 1; Mismatches 5; Indels 0; Gaps 0;

Qy	145	RRLFAFOASCPAPSSRDRGCRPEEGPRCLRYAGLVGUGVTVTPNLYDNVARVAPKGCB	Db	9 RRLFAFOASCPAPSSRDRGCRPEEGPRCLRYAGLVGUGVTVTPNLYDNVARVAPKGCA	6 68
Qy	205	A S G N R R E C E A P R K L F T R N P C I D G A T Q A F D S Q P S V I Q D Q	Db	69 A S G N R R E C E A P R K L F T R N P C I D G A T Q A F D S Q P S V I Q D Q	1 0 8

PATENT NO. 6380362  
 PATENT NO. 6666259  
 GENERAL INFORMATION:  
 APPLICANT: Ibanez, Carlos P.  
 APPLICANT: Arumae, Utmas  
 APPLICANT: Sarola, Hannu  
 APPLICANT: Suvaro, Petro  
 APPLICANT: Trupp, Miles  
 APPLICANT: Saarma, Mart  
 TITLE OF INVENTION: Glial Cell Line-Derived Neurotropic Factor Receptors  
 FILE REFERENCE: CEPHO418  
 CURRENT APPLICATION NUMBER: US/08/861,990  
 CURRENT FILING DATE: 1997-05-22

PRIOR APPLICATION NUMBER: 08/747,842  
 PRIOR FILING DATE: 1996-11-13  
 PRIOR APPLICATION NUMBER: 60/006,619  
 PRIOR FILING DATE: 1995-11-13  
 PRIOR APPLICATION NUMBER: 60/015,767  
 PRIOR FILING DATE: 1996-04-16  
 PRIOR APPLICATION NUMBER: 60/021,965  
 PRIOR FILING DATE: 1996-06-27  
 PRIOR APPLICATION NUMBER: 60/020,638  
 PRIOR FILING DATE: 1996-06-27  
 PRIOR APPLICATION NUMBER: 60/020,639  
 PRIOR FILING DATE: 1996-06-27  
 NUMBER OF SEQ ID NOS: 11  
 SOFTWARE: PatentIn Ver. 2.1  
 SEQ ID NO: 11  
 LENGTH: 445  
 TYPE: PRT  
 ORGANISM: Rattus sp.  
 US-08-861-990-11

Query Match Score 469; DB 4; Length 445;  
 Best Local Similarity 43.0%; Pred. No. 1.7e-35;  
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRNCVAAEACTADEOCQQLSERVVAQCLGRAGWRGPGSCVSRCLRRFFAR 88  
 Db 153 AVSTKSNHCLDAAKACNLNDCKKLRSYISICNREIS--PTERCRNRKCHKALRQFFDR 210  
 Qy 89 GPPALTHALLFCGGCGPACACERRQTAPACMFGPQLAPPSCIKPLDRCRSRRCRCPRL 148  
 Db 211 VRSBYTYMLFCSQDQACERRQTLPSGSYEDKE--KPNCLDLRSLCITDHLCRSRL 268  
 Qy 149 FAFOASCAPAPGSRDGCPEEGPRCLRAYAGLNGVTPVNLDN--VSARVAPWGCEAS 206  
 Db 269 ADFHANCRASYRTITSCHADNYOIGSYAGMIGFDWMPVNUSNPTGIVSPWCNGRS 328  
 Qy 207 GNRBECFAKLFTRNCPLDGAQAF 233  
 Db 329 GNMBEECEKFLRDTENPCLRNAIQAF 355

RESULT 3  
 US-08-957-063-6  
 Sequence 6, Application US/08957063  
 Patent No. 6025157  
 GENERAL INFORMATION:  
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes  
 TITLE OF INVENTION: Neurturin Receptor  
 NUMBER OF SEQUENCES: 19  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Genentech, Inc.  
 STREET: 1 DNA Way  
 CITY: South San Francisco  
 STATE: California  
 COUNTRY: USA  
 ZIP: 94080

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: WinPatin (Genentech)

CURRENT APPLICATION DATA:  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/957,685  
 FILING DATE: 19-Jan-2000  
 CLASSIFICATION: <Unknown>  
 APPLICATION NUMBER: 08/957,685  
 FILING DATE: <Unknown>  
 FILING DATE: 18-Feb-1997  
 CLASSIFICATION: <Unknown>  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Torchia, PhD, Timothy E.  
 REGISTRATION NUMBER: 36,700  
 REFERENCE/DOCKET NUMBER: P1086P2

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650/225-8674  
 TELEFAX: 650/952-9881  
 INFORMATION FOR SEQ ID NO: 6:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 464 amino acids  
 TYPE: Amino Acid

RESULT 4  
 US-09-487-685-6  
 Sequence 6, Application US/09487685  
 Patent No. 634248  
 GENERAL INFORMATION:  
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes  
 TITLE OF INVENTION: Neurturin Receptor  
 NUMBER OF SEQUENCES: 19  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Genentech, Inc.  
 STREET: 1 DNA Way  
 CITY: South San Francisco  
 STATE: California  
 COUNTRY: USA  
 ZIP: 94080

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: WinPatin (Genentech)

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/487,685  
 FILING DATE: 19-Jan-2000  
 CLASSIFICATION: <Unknown>  
 APPLICATION NUMBER: 08/957,063  
 FILING DATE: <Unknown>  
 FILING DATE: 18-Feb-1997  
 CLASSIFICATION: <Unknown>  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Torchia, PhD, Timothy E.  
 REGISTRATION NUMBER: 36,700  
 REFERENCE/DOCKET NUMBER: P1086P2

TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650/225-8674  
 TELEFAX: 650/952-9881  
 INFORMATION FOR SEQ ID NO: 6:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 464 amino acids  
 TYPE: Amino Acid

```

; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
Db 211 VPSEYTRMLFCSCQDQACABERRRQTLPSCSYEDKE--KPNCLDLRSLCRDHLCRSRL 268
Query Match 33.2%; Score 469; DB 3; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35; Mismatches 79; Indels 6; Gaps 3;
Matches 89; Conservative 33; MisMatches 79;

Qy 29 ASSTEGRCVVAEACTADEQCOQLRSBYAQCLGRAGWGRPGSCVSRSRCAALRFFPAR 88
Db 153 AVSTKSNCIDAKACBLNDCKKLRSYISCNREIS--PTECRNRRKCKALRQFDR 210
Qy 89 GPALTHALLFGCGCEGCAERROTFAPACAFSGPQLAPPSCLKPLDRERSRRCPRL 148
Db 153 AVSTKSNCIDAKACBLNDCKKLRSYISCNREIS--PTECRNRRKCKALRQFDR 210
Qy 211 VPSEYTRMLFCSCQDQACABERRRQTLPSCSYEDKE--KPNCLDLRSLCRDHLCRSRL 268
Qy 149 FAFOQASCAPAPGSRSRDGGCPEEGGPRCLRAYAGLVGTWTPTNLDN--VSARVAPWCGCEAS 206
Db 269 ADPHANCRASRTITSCTPADNVQACIGSYACMIGFDWTPTNVTDSNPTGIVVSPWCNRGS 328
Qy 207 GNRREECAFRLKFTRNPCLODGAQAF 233
Db 329 GMEEBECFKPLDFTENPCLNQAF 355

RESULT 5
US-01-802-805D-5
; Sequence 6, Application US/08802805D
; Patent No. 6372453
; GENERAL INFORMATION:
    APPLICANT: Robert D. Klein
    TITLE OF INVENTION: Neurturin Receptor
    NUMBER OF SEQUENCES: 28
    CORRESPONDENCE ADDRESS:
        ADDRESSEE: Genentech, Inc.
        STREET: 1 DNA Way
        CITY: South San Francisco
        STATE: California
        COUNTRY: USA
        ZIP: 94080
    COMPUTER READABLE FORM:
        MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
    COMPUTER: IBM PC compatible
    OPERATING SYSTEM: PC-DOS/MS-DOS
    SOFTWARE: WinPatin (Genentech)

CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/08/802, 805D
    FILING DATE: 18-Feb-1997
    CLASSIFICATION: 536
    ATTORNEY/AGENT INFORMATION:
        NAME: Torchia, PhD , Timothy E.
        REGISTRATION NUMBER: 36,700
        REFERENCE/DOCKET NUMBER: P1086
    TELECOMMUNICATION INFORMATION:
        TELEPHONE: 650/221-8674
        TELEFAX: 650/952-9881
    INFORMATION FOR SEQ ID NO: 6:
    SEQUENCE CHARACTERISTICS:
        LENGTH: 464 amino acids
        TYPE: Amino Acid
        TOPOLOGY: Linear
; US-08-802-805D-6

Query Match 33.2%; Score 469; DB 3; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35; Mismatches 79; Indels 6; Gaps 3;
Matches 89; Conservative 33; MisMatches 79;

Qy 29 ASSTEGRCVVAEACTADEQCOQLRSBYAQCLGRAGWGRPGSCVSRSRCAALRFFPAR 88
Db 153 AVSTKSNCIDAKACBLNDCKKLRSYISCNREIS--PTECRNRRKCKALRQFDR 210
Qy 89 GPALTHALLFGCGCEGCAERROTFAPACAFSGPQLAPPSCLKPLDRERSRRCPRL 148
Db 153 AVSTKSNCIDAKACBLNDCKKLRSYISCNREIS--PTECRNRRKCKALRQFDR 210
Qy 211 VPSEYTRMLFCSCQDQACABERRRQTLPSCSYEDKE--KPNCLDLRSLCRDHLCRSRL 268
Qy 149 FAFOQASCAPAPGSRSRDGGCPEEGGPRCLRAYAGLVGTWTPTNLDN--VSARVAPWCGCEAS 206
Db 269 ADPHANCRASRTITSCTPADNVQACIGSYACMIGFDWTPTNVTDSNPTGIVVSPWCNRGS 328
Qy 207 GNRREECAFRLKFTRNPCLODGAQAF 233
Db 329 GMEEBECFKPLDFTENPCLNQAF 355

RESULT 6
US-08-861-990-2
; Sequence 2, Application US/08861990
; Patent No. 6696259
; GENERAL INFORMATION:
    APPLICANT: Ibanez, Carlos P.
    APPLICANT: Arume, Urmas
    APPLICANT: Sariola, Hannu
    APPLICANT: Suvanto, Petro
    APPLICANT: Trupp, Miles
    APPLICANT: Saarna, Mart
    TITLE OF INVENTION: Glial Cell Line-Derived Neurotropic Factor Receptors
    FILE REFERENCE: GEPHO418
    CURRENT APPLICATION NUMBER: US/08/861, 990
    CURRENT FILING DATE: 1997-05-22
    PRIOR APPLICATION NUMBER: 08/747, 842
    PRIOR FILING DATE: 1996-11-13
    PRIOR APPLICATION NUMBER: 60/006, 619
    PRIOR FILING DATE: 1995-11-13
    PRIOR APPLICATION NUMBER: 60/015, 767
    PRIOR FILING DATE: 1996-04-16
    PRIOR APPLICATION NUMBER: 60/021, 965
    PRIOR FILING DATE: 1996-06-27
    PRIOR APPLICATION NUMBER: 60/020, 638
    PRIOR FILING DATE: 1996-06-27
    PRIOR APPLICATION NUMBER: 60/020, 639
    PRIOR FILING DATE: 1996-06-27
    PRIOR APPLICATION NUMBER: 60/020, 639
    NUMBER OF SEQ ID NOS: 11
    SEQ ID NO 2
    LENGTH: 464
    TYPE: PRT
    ORGANISM: Rattus sp.
; US-08-861-990-2

Query Match 33.2%; Score 469; DB 4; Length 464;
Best Local Similarity 43.0%; Pred. No. 1.8e-35; Mismatches 79; Indels 6; Gaps 3;
Matches 89; Conservative 33; MisMatches 79;

Qy 29 ASSTEGRCVVAEACTADEQCOQLRSBYAQCLGRAGWGRPGSCVSRSRCAALRFFPAR 88
Db 153 AVSTKSNCIDAKACBLNDCKKLRSYISCNREIS--PTECRNRRKCKALRQFDR 210
Qy 89 GPALTHALLFGCGCEGCAERROTFAPACAFSGPQLAPPSCLKPLDRERSRRCPRL 148
Db 153 AVSTKSNCIDAKACBLNDCKKLRSYISCNREIS--PTECRNRRKCKALRQFDR 210
Qy 211 VPSEYTRMLFCSCQDQACABERRRQTLPSCSYEDKE--KPNCLDLRSLCRDHLCRSRL 268
Qy 149 FAFOQASCAPAPGSRSRDGGCPEEGGPRCLRAYAGLVGTWTPTNLDN--VSARVAPWCGCEAS 206
Db 269 ADPHANCRASRTITSCTPADNVQACIGSYACMIGFDWTPTNVTDSNPTGIVVSPWCNRGS 328
Qy 207 GNRREECAFRLKFTRNPCLODGAQAF 233
Db 329 GMEEBECFKPLDFTENPCLNQAF 355

RESULT 7
US-09-388-316C-6
; Sequence 6, Application US/09388316C
; Patent No. 6777196
; GENERAL INFORMATION:
    APPLICANT: KLEIN, ROBERT D.

```

APPLICANT: ROSENTHAL, ARNON  
 APPLICANT: HYNES, MARY A.  
 TITLE OF INVENTION: NEUPTURIN RECEPTOR  
 FILE REFERENCE: GENENT-45A2D1  
 CURRENT APPLICATION NUMBER: US/09/388,316C  
 PRIORITY APPLICATION NUMBER: 07/024,665  
 PRIORITY FILING DATE: 1998-02-17  
 PRIORITY APPLICATION NUMBER: 60/063,258  
 PRIORITY FILING DATE: 1997-10-24  
 PRIORITY APPLICATION NUMBER: 60/049,818  
 PRIORITY FILING DATE: 1997-06-09  
 PRIORITY APPLICATION NUMBER: 60/038,839  
 PRIORITY FILING DATE: 1997-02-18  
 SOFTWARE: FastSEQ for Windows Version 4.0  
 SEQ ID NO: 6  
 LENGTH: 464  
 TYPE: PRY  
 ORGANISM: Ratticus norvegicus  
 US-09-388-316C-6

Query Match 33.2%; Score 469; DB 4; Length 464;  
 Best Local Similarity 43.0%; Pred. No. 1.8e-35; Mismatches 79; Indels 6; Gaps 3;  
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRVCVAEACTADEQOCQLRSBYYQCLGRAGWRGSCVRSRCRALRFFAR 88  
 Db 153 AVSTKSNHCLDAKACAKCNLNDCKKRSYISICNREIS--PTERCNRKCHKALRQFFDR 210

Qy 89 GPPALTHALIPCGGPGACACERROTEFACAFSGPQLAPPSCUKPLRCCRRCRPRL 148  
 Db 211 VPSEYTRMLFCSCQDQACAKERROTIPLSCSYEDKE--KPNCLDLRSLSRCTDHLCRSRL 268

Qy 149 FAPOASCAPAPGSRGCGPEEGPRCLRAYAGLVGTUTPNYLON--VSARVADWGCAS 206  
 Db 268 329 GNMEEBECEKFIRDFTENPCURNAIQAF 355

Db 269 ADFHANCRAKYRTTSCPADNYOACLGSYAGMIGFDMTPNYVDNSPTGIVVSPWCNGS 206

Qy 207 GNRREBCEAFRKLFTRNPCLDGAQAF 233

Db 329 GNMEEBECEKFIRDFTENPCURNAIQAF 355

RESULT 8  
 US-09-957-063-18  
 Sequence 18, Application US/08957-063  
 ; Sequence 18, Application US/08957-063  
 ; Patent No. 625157  
 ; GENERAL INFORMATION:  
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes  
 TITLE OF INVENTION: Neurturin Receptor  
 NUMBER OF SEQUENCES: 19  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Genentech, Inc.  
 STREET: 1 DNA Way  
 CITY: South San Francisco  
 STATE: California  
 COUNTRY: USA  
 ZIP: 94080

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: WinPatin (Genentech)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/957,063  
 FILING DATE: 24-Oct-1997  
 CLASSIFICATION: 800  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 08/871  
 FILING DATE: 9-Jun-1997  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 913  
 FILING DATE: 18-Feb-1997

ATTORNEY/AGENT INFORMATION:  
 NAME: Torchia, PhD., Timothy E.  
 REGISTRATION NUMBER: 36,700  
 REFERENCE/DOCKET NUMBER: P1086P2  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650/952-9881  
 INFORMATION FOR SEQ ID NO: 18:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 664 amino acids  
 TYPE: Amino Acid  
 TOPOLOGY: Linear  
 US-08-957-063-18

Query Match 33.2%; Score 469; DB 3; Length 664;  
 Best Local Similarity 43.0%; Pred. No. 2.8e-35; Mismatches 79; Indels 6; Gaps 3;  
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRVCVAEACTADEQOCQLRSBYYQCLGRAGWRGSCVRSRCRALRFFAR 88  
 Db 153 AVSTKSNHCLDAKACAKCNLNDCKKRSYISICNREIS--PTERCNRKCHKALRQFFDR 210

Qy 89 GPPALTHALIPCGGPGACACERROTEFACAFSGPQLAPPSCUKPLRCCRRCRPRL 148  
 Db 211 VPSEYTRMLFCSCQDQACAKERROTIPLSCSYEDKE--KPNCLDLRSLSRCTDHLCRSRL 268

Qy 149 FAPOASCAPAPGSRGCGPEEGPRCLRAYAGLVGTUTPNYLON--VSARVADWGCAS 206  
 Db 268 329 GNMEEBECEKFIRDFTENPCURNAIQAF 355

RESULT 9  
 US-09-487-685-18  
 Sequence 18, Application US/09487-685  
 ; Sequence 18, Application US/09487-685  
 ; Patent No. 634348  
 ; GENERAL INFORMATION:  
 APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes  
 TITLE OF INVENTION: Neurturin Receptor  
 NUMBER OF SEQUENCES: 19  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Genentech, Inc.  
 STREET: 1 DNA Way  
 CITY: South San Francisco  
 STATE: California  
 COUNTRY: USA  
 ZIP: 94080

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: WinPatin (Genentech)  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/487,685  
 FILING DATE: 19-Jan-2000  
 CLASSIFICATION: <Unknown>  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: 08/957,063  
 FILING DATE: <Unknown>  
 APPLICATION NUMBER: 913  
 FILING DATE: 18-Feb-1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Torchia, PhD., Timothy E.  
 REGISTRATION NUMBER: 36,700  
 REFERENCE/DOCKET NUMBER: P1086P2  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 650/952-9881  
 INFORMATION FOR SEQ ID NO: 18:  
 SEQUENCE CHARACTERISTICS:

Query Match 33.2%; Score 469; DB 3; Length 664;  
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;  
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Qy 29 ASSTEGNRCVVEAECTADEQOCQLRSYVAOCLGRAGWRGPSCVSRCAARRRPAR 88  
 Db 153 AVSTKSNHCLDAKACNLNDCKKLASSYISICNRBIS--PTECRNRKCHKAQFDFR 210

Qy 89 GPPALTHALLFCGCGEGPACABERRQTPAPACFGSPOLAPSCLKPLDRCRSSRCPRL 148  
 Db 211 VPSBYTYRMFLFCSCQDQAERROTILPSCSYEDKE--KPNCLDLRSLCRTDHLCSRL 268

Qy 149 FAFOQASCAPAPGSRDGCPEEGPRCLRAYAGLVGLVGTWTPNLDN--VSARVAPWCGBEAS 206  
 Db 269 ADPHANCRASYRTITSCPADNYQACLGSYAGMIGFDMTPTNVDNSNPTGIVVSPWCNCRG 328

Qy 207 GNRRECECAFRLKFLTRNPLCQDGAIQF 233  
 Db 329 GMNEEECEKFRLDFTENPCLRNIAIQF 355

RESULT 10

US-08-802-805D-18

; Sequence 18, Application US/08802805D

Patent No. 637453

GENERAL INFORMATION:

; APPLICANT: Robert D. Klein

; TITLE OF INVENTION: Neurturin Receptor

; NUMBER OF SEQUENCES: 28

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 1 DNA Way

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08-802, 805D

; FILING DATE: 18-Feb-1997

; CLASSIFICATION: 535

ATTORNEY/AGENT INFORMATION:

; NAME: Torchia, PhD, Timothy E.

; REGISTRATION NUMBER: 36,700

; REFERENCE/DOCKET NUMBER: P1086

TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650/952-8674

; TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 18:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 664 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

US-08-802-805D-18

Query Match 33.2%; Score 469; DB 3; Length 664;  
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;  
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Qy 89 GPPALTHALLFCGCGEGPACABERRQTPAPACFGSPOLAPSCLKPLDRCRSSRCPRL 148  
 Db 211 VPSBYTYRMFLFCSCQDQAERROTILPSCSYEDKE--KPNCLDLRSLCRTDHLCSRL 268

Qy 149 FAFOQASCAPAPGSRDGCPEEGPRCLRAYAGLVGLVGTWTPNLDN--VSARVAPWCGBEAS 206  
 Db 269 ADPHANCRASYRTITSCPADNYQACLGSYAGMIGFDMTPTNVDNSNPTGIVVSPWCNCRG 328

Qy 207 GNRRECECAFRLKFLTRNPLCQDGAIQF 233  
 Db 329 GMNEEECEKFRLDFTENPCLRNIAIQF 355

RESULT 11

US-09-388-316C-18

; Sequence 18, Application US/09388316C

Patent No. 6777196

GENERAL INFORMATION:

; APPLICANT: KUBIN, ROBERT D.

; APPLICANT: ROSENTHAL, ARNON

; APPLICANT: HYNE, MARY A.

; TITLE OF INVENTION: NEURTURIN RECEPTOR

; FILE REFERENCE: GENENT-45A2v1

; CURRENT APPLICATION NUMBER: US/09/388,316C

; PRIOR APPLICATION NUMBER: 09/024,665

; PRIOR FILING DATE: 1998-02-17

; PRIOR FILING DATE: 1999-09-01

; PRIOR APPLICATION NUMBER: 60/063, 258

; PRIOR FILING DATE: 1997-10-24

; PRIOR FILING DATE: 1997-06-09

; PRIOR APPLICATION NUMBER: 60/038,839

; PRIOR FILING DATE: 1997-02-18

; NUMBER OF SEQ ID NOS: 30

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO: 18

; LENGTH: 664

; TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: This sequence is a fusion protein comprising rat NTM<sup>alpha</sup> sequence and human FC sequence.

US-09-388-316C-18

Query Match 33.2%; Score 469; DB 4; Length 664;  
 Best Local Similarity 43.0%; Pred. No. 2.8e-35;  
 Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Qy 29 ASSTEGNRCVVEAECTADEQOCQLRSYVAOCLGRAGWRGPSCVSRCAARRRPAR 88  
 Db 153 AVSTKSNHCLDAKACNLNDCKKLASSYISICNRBIS--PTECRNRKCHKAQFDFR 210

Qy 89 GPPALTHALLFCGCGEGPACABERRQTPAPACFGSPOLAPSCLKPLDRCRSSRCPRL 148  
 Db 211 VPSBYTYRMFLFCSCQDQAERROTILPSCSYEDKE--KPNCLDLRSLCRTDHLCSRL 268

Qy 149 FAFOQASCAPAPGSRDGCPEEGPRCLRAYAGLVGLVGTWTPNLDN--VSARVAPWCGBEAS 206  
 Db 269 ADPHANCRASYRTITSCPADNYQACLGSYAGMIGFDMTPTNVDNSNPTGIVVSPWCNCRG 328

Qy 207 GNRRECECAFRLKFLTRNPLCQDGAIQF 233  
 Db 329 GMNEEECEKFRLDFTENPCLRNIAIQF 355

RESULT 12

US-09-187-906-9

; Sequence 9, Application US/09187906

Patent No. 6677135

GENERAL INFORMATION:

; APPLICANT: BIOCEN, INC.

; TITLE OF INVENTION: Ret. Ligand (RetL) for Stimulating Neural and Renal Growth

NUMBER OF SEQUENCES: 21  
 CORRESPONDENCE ADDRESS:  
 ADDRESSE: Biogen, Inc.  
 STREET: 14 Cambridge Center  
 CITY: Cambridge  
 STATE: MA  
 COUNTRY: USA  
 ZIP: 02142  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/187,906  
 FILING DATE:  
 CLASSIFICATION:  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: PCT/US97/07726  
 FILING DATE: 07-MAY-97  
 APPLICATION NUMBER: US 60/017,427  
 FILING DATE: 08-MAY-96  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 60/019,300  
 FILING DATE: 07-JUN-96  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 60/021,859  
 FILING DATE: 16-JUL-96  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 60/043,533  
 FILING DATE: 10-AUG-97  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Kaplan, Warren A.  
 REGISTRATION NUMBER: 34,199  
 REFERENCE/DOCKET NUMBER: A008 PCT CIP  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-679-2400  
 TELEFAX: 617-679-2838  
 INFORMATION FOR SEQ ID NO: 9:  
 LENGTH: 346 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein  
 US-09-187-906-9

---

Query Match 32.9%; Score 465; DB 4; Length 346;  
 Best Local Similarity 41.9%; Pred. No. 4.3e-35;  
 Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;  
 Qy 33 EGNRCAEAACTADEQCOOLRSVYVACIGRAGWRGPGSCVSRCRARLRFARGPPA 92  
 Db 145 KGNNDLDAKACNNDICKYRSAYITPCTTSV--SNDVCRNRKCHALRQFFDKVPAK 201  
 Qy 93 LTHALLFCGCGPACERKRQTFAPACFSGPOLAPPCLIKPDRCBERSRCRPFHQ 152  
 Db 202 HSGLMLFCSCRDIACTERBRQTIVPVCSE--EREKPNLNLQSKCKNYICKSLADPF 259  
 Qy 153 ASCAPAPGSRDGCPEGGRCLAYAGVGTGTVTPMYDNVSARVAPPGCEASGRRE 212  
 Db 260 TNQOPESRSVSSCILKENTADCLAYSLGJIGTWTMPNYIDSSLSSVAPWDCNSGNIDEE 319  
 Qy 93 LTHALLFCGCGPACERKRQTFAPACFSGPOLAPPCLIKPDRCBERSRCRPFHQ 152  
 Db 88 HSYGMFLFCSRDIACTERBRQTIVPVCSE--EREKPNLNLQSKCKNYICKSLADPF 145  
 Qy 153 ASCAPAPGSRDGCPEGGRCLAYAGVGTGTVTPMYDNVSARVAPPGCEASGRRE 212  
 Db 146 TNQOPESRSVSSCILKENTADCLAYSLGJIGTWTMPNYIDSSLSSVAPWDCNSGNIDEE 205  
 Qy 213 CEAFRKLFTRNPCLDGAQAFDSQSPSTLQDQMP 247  
 Db 320 CLKFLNFFKDNTCLKNAIQAFGNGSDVTW--WQP 351

RESULT 14  
 US-09-187-906-11  
 Sequence 11, Application US/09187906  
 Patent No. 6677135  
 GENERAL INFORMATION:  
 APPLICANT: Biogen, Inc.  
 TITLE OF INVENTION: Ret Ligand (Ret) for Stimulating Neural  
 NUMBER OF SEQUENCES: 21  
 CORRESPONDENCE ADDRESS:  
 ADDRESSE: Biogen, Inc.  
 STREET: 14 Cambridge Center  
 CITY: Cambridge  
 STATE: MA  
 COUNTRY: USA  
 ZIP: 02142  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS

RESULT 13  
 US-09-805D-22  
 Sequence 22, Application US/08802805D  
 Patent No. 6372453  
 GENERAL INFORMATION:  
 APPLICANT: Robert D. Klein

SOFTWARE: Patentin Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/187,906  
 FILING DATE: 08-MAY-96  
 CLASSIFICATION:  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: PCT/US97/07726  
 FILING DATE: 07-MAY-97  
 APPLICATION NUMBER: US 60/117,427  
 FILING DATE: 08-MAY-96  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 60/019,300  
 FILING DATE: 07-JUN-96  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 60/021,859  
 FILING DATE: 16-JUL-96  
 PRIORITY APPLICATION DATA:  
 APPLICATION NUMBER: US 60/043,533  
 FILING DATE: 10-APR-97  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Kaplan, Warren A.  
 REGISTRATION NUMBER: 34,199  
 REFERENCE/DOCKET NUMBER: A008 PCT CIP  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 617-679-2800  
 TELEFAX: 617-679-2838  
 INFORMATION FOR SEQ ID NO: 11:  
 LENGTH: 460 amino acids  
 TYPE: amino acid  
 TOPOLOGY: linear  
 MOLECULE TYPE: protein

---

SEQ ID NO 10  
 LENGTH: 463  
 TYPE: PPT  
 ORGANISM: HUMAN  
 FEATURE:  
 NAME/KEY: misc\_feature  
 LOCATION: (51)..(5)  
 OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser.  
 NAME/KEY: misc\_feature  
 LOCATION: (1)..(537)  
 OTHER INFORMATION: No. 6455277E = "1 to 537 is -235 to 301 of Figure 5 2iacon"  
 NAME/KEY: misc\_feature  
 LOCATION: (550)..(550)  
 OTHER INFORMATION: N in position 550 indicates any nucleic acid  
 US-08-837-199A-10

---

Query Match 32.9%; Score 465; DB 4; Length 463;  
 Best Local Similarity 41.9%; Pred. No. 4; 3e-35;  
 Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;  
 Qy 33 EGNRVCVERAECYTADEOCQOLASEYVQCLGRAGWGRGSCVSRSRCRALRRFARGPPA 92  
 Db 150 KGNCLDAAKACNLLDDICKKKYRSAYITPCTTSV--SNDVCNRKCKHAKRQFDKVAK 206  
 Qy 93 LTHALIIFCGCEGPACABRRQTFAPACAFSGQLAPSLPSLKDPRCERSRRCPRLRFQ 152  
 Db 207 HSTGMLFCSCRDFACTERRQTIVPVESE--ERBKNCNLQDSKTNVICHESLRADP 264  
 Qy 153 ASCAPAPGSRDGPEEGPRCLRAYAGLVGTVTPNLDNSARVAPWCGCEASGRBEE 212  
 Db 265 TNQCPERSRSVSSLSKENVADCLLAYSGLTGTTWMPNVDSSLSVAPWCDNSGNDLBE 324  
 Qy 213 CEAFRKLFPTTRNPCLDGAQAFPSSQSPVLIQDQNNP 247



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

## OM protein - protein search, using SW model

Run on: January 26, 2005, 12:53:26 ; Search time 158 Seconds

(without alignments)  
585.773 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MLSCAYLRLVNLNERPGQAVW. .... SVLQDQWMNPYQNAQGQAKTEA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqB, 35872999 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database :

- A\_Geneseq\_23Sep04:\*\*
- 1: geneseqD1980s:\*\*
- 2: geneseqD1990s:\*\*
- 3: geneseqD2000s:\*\*
- 4: geneseqD2001s:\*\*
- 5: geneseqD2002s:\*\*
- 6: geneseqD2003as:\*\*
- 7: geneseqD2003bs:\*\*
- 8: geneseqD2004s:\*\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1413	100.0	258	4 ABB61637
2	1386	98.1	273	4 ABB61636
3	1078	76.3	277	4 ABB62103
4	1078	76.3	476	4 ABB62107 Murine Ret
5	1075.5	76.1	260	4 ABB62106 Mouse Ret
6	1075.5	76.1	260	4 ABB09214 Mouse GPT
7	1075.5	76.1	293	4 ABB09215 Mouse put
8	1028.5	72.8	264	4 ABB62104 Mouse Ret
9	927	65.6	340	4 ABB42771 Murine GPT
10	920.5	65.1	269	4 ABB09217 Human Ret
11	914.5	64.7	282	4 ABB62105 Human Ret
12	767.5	54.3	299	4 ABB09218 Human put
13	649.5	46.0	182	4 ABB09219 Human put
14	569.5	40.3	190	4 ABB09216 Mouse Sec
15	515	36.4	132	5 ABB72385 Murine pr
15	515	36.4	132	5 ABB72385 Murine pr
17	469	33.2	460	2 ABB84181 A GDNFR-a
18	469	33.2	464	2 ABB71602 Rat neurt
19	469	33.2	454	2 ABB92299 Rat GDNFR
20	469	33.2	464	3 ABB80122 Rat neurt
21	469	33.2	464	3 ABB79036 Rat neurt
22	469	33.2	464	5 ABB09630 Amino aci
23	469	33.2	464	5 ABB79266 Rat neurt
24	469	33.2	464	7 ADD11657 Rat Neurt
25	33.2	464	7 ADD54591 Rat Prote	

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database :

- A\_Geneseq\_23Sep04:\*\*
- 1: geneseqD1980s:\*\*
- 2: geneseqD1990s:\*\*
- 3: geneseqD2000s:\*\*
- 4: geneseqD2001s:\*\*
- 5: geneseqD2002s:\*\*
- 6: geneseqD2003as:\*\*
- 7: geneseqD2003bs:\*\*
- 8: geneseqD2004s:\*\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## ALIGNMENTS

26	469	33.2	464	7 ADE63251 Rat Prote
27	469	33.2	664	2 AAW71604 Rat neur
28	469	33.2	664	3 AAY80124 Rat NTR
29	469	33.2	664	5 ABB79038 Rat NTR
30	469	33.2	664	5 ABB09632 Rat neur
31	469	33.2	664	5 ABB79268 Rat NTR
32	469	33.2	664	7 ADD11659 Rat NTR
33	469	33.2	951	3 AAY15180 Rat
34	467	33.1	330	2 AAW81627 TGF
35	465	32.9	346	2 AAW37458 Human Ret
36	465	32.9	346	8 ADD58701 Human ret
37	465	32.9	411	2 AAW81625 Mouse mat
38	465	32.9	460	2 AAW37459 Human Ret
39	465	32.9	460	3 AAY15175 Human GPR
40	465	32.9	460	6 ABB9180 Tumour-as
41	465	32.9	460	8 ADJ58703 Human ret
42	465	32.9	463	2 AAW81624 Mouse TGF
43	465	32.9	463	2 AAW81617 GDNFR-1alp
44	465	32.9	463	2 AAW84166 GDNFR-1lp
45	465	32.9	465	2 AAW35333 Human gli

SQ	Sequence 258 AA;
CC	(see AAF31061) is localised on chromosome 3q5
XX	Sequence 273 AA;
Query Match	98.1%; Score 1386; DB 4; Length 273;
Best Local Similarity	100.0%; Pred. No. 2.1e-123;
Matches	258; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MSGAYVRLVNRPGQAVLWLSGCGRSASSTEGNRCEAECTADBEQCOOLSERVAQ 60
Db	1 MSGAYVRLVNRPGQAVLWLSGCGRSASSTEGNRCEAECTADBEQCOOLSERVAQ 60
QY	61 CIGRAGIRGPQGCVRSCRRALRFARGPPALTHALIFCGCERGRQFTRAPAC 120
Db	61 CIGRAGIRGPQGCVRSCRRALRFARGPPALTHALIFCGCERGRQFTRAPAC 120
QY	121 FSGPQLAPPSCIKPLDRCSRSRCPRLFAQASCAPGSRGDGCBEGGRCLRAYGL 180
Db	121 FSGPQLAPPSCIKPLDRCSRSRCPRLFAQASCAPGSRGDGCBEGGRCLRAYGL 180
QY	181 VGTVVTPNVLDSARVAPWCCCEASGNRRECEAFLRKLFTRNPCLDGAIOAFDSSQPSV 240
Db	181 VGTVVTPNVLDSARVAPWCCCEASGNRRECEAFLRKLFTRNPCLDGAIOAFDSSQPSV 240
QY	241 LQDQWNPYQNAQAKWEA 258
Db	241 LQDQWNPYQNAQAKWEA 258
RESULT 2	
ID	AAB61636
ID	AAB61636 standard; protein; 273 AA.
AC	AAB61636;
XX	
XX	06-APR-2001 (first entry)
DB	Rat GFRalpha-4 splice variant A.
XX	
KW	Rat; GFRalpha-4; carcinoma; familial hirschsprung disease; pain; glial cell-line derived neurotrophic factor; neurodegenerative disease; GDNP family receptor alpha-4; Alzheimer's disease; Parkinson's disease; motor neuron disease; peripheral neuropathy; spinal cord injury; chromosome 3q5.
KW	Rattus rattus.
XX	WO200102557-A1.
XX	
PD	11-JAN-2001.
XX	
PF	26-MAY-2000; 2000WO-EP004918.
XX	
PR	29-JUN-1999; 99GB-00015200.
XX	
PA	(JANIC ) JANSSEN PHARM NV.
XX	
PI	Masue SJ, Cik M, Hoefnagel EW;
XX	
DR	WPT; 2001-138137/14.
XX	
PS	N-PSDB; AAP31061, AAP31062.
XX	
PT	Gliaal cell-line derived neurotrophic factor family receptor alpha-4, useful for preparing medicaments for treating neurodegenerative diseases (e.g. Alzheimer's disease, Parkinson's disease) and carcinomas.
XX	Claim 14; Page 73-74; 82pp; English.
CC	The present sequence is rat Glial cell-line Derived Neurotrophic Factor (GNF) family receptor alpha-4 (GFRalpha-4) splice variant A. GFRalpha-4 is useful in the preparation of a medicament for the treatment of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, motor neuron disease, peripheral neuropathy, spinal cord injury, familial hirschsprung disease, carcinomas, and diseases associated with GFRalpha-4 gene receptor dysfunction and in alleviating pain. The rat GFRalpha-4 gene
XX	
CC	is localised on chromosome 3q5
XX	Sequence 273 AA;
Query Match	98.1%; Score 1386; DB 4; Length 273;
Best Local Similarity	100.0%; Pred. No. 7.5e-121;
Matches	258; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1 MSGAYVRLVNRPGQAVLWLSGCGRSASSTEGNRCEAECTADBEQCOOLSERVAQ 60
Db	1 MSGAYVRLVNRPGQAVLWLSGCGRSASSTEGNRCEAECTADBEQCOOLSERVAQ 60
QY	61 CIGRAGIRGPQGCVRSCRRALRFARGPPALTHALIFCGCERGRQFTRAPAC 120
Db	61 CIGRAGIRGPQGCVRSCRRALRFARGPPALTHALIFCGCERGRQFTRAPAC 120
QY	121 FSGPQLAPPSCIKPLDRCSRSRCPRLFAQASCAPGSRGDGCBEGGRCLRAYGL 180
Db	121 FSGPQLAPPSCIKPLDRCSRSRCPRLFAQASCAPGSRGDGCBEGGRCLRAYGL 180
QY	181 VGTVVTPNVLDSARVAPWCCCEASGNRRECEAFLRKLFTRNPCLDGAIOAFDSSQPSV 240
Db	181 VGTVVTPNVLDSARVAPWCCCEASGNRRECEAFLRKLFTRNPCLDGAIOAFDSSQPSV 240
QY	241 LQDQWNPYQNAQAKWEA 258
Db	241 LQDQWNPYQNAQAKWEA 258
RESULT 3	
ID	AAB62103
ID	AAB62103 standard; protein; 277 AA.
AC	AAB62103;
XX	
AC	AAB62103;
XX	
DT	29-MAY-2001 (first entry)
XX	
DE	Mouse RetL5 polypeptide.
XX	
KW	Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic; Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse; vulnerability; nootropic; anti-HIV; neuroprotective; antibacterial; cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.
KW	XX
OS	Mus sp.
OS	
XX	
FH	Key Location/Qualifiers
FT	Peptide 1..21
FT	/note= "signal peptide"
FT	Protein 22..277
FT	/note= "mature protein"
XX	
PN	WO200116169-A2.
XX	
PD	08-MAR-2001.
XX	
PF	01-SEP-2000; 2000WO-US02411.
XX	
PR	01-SEP-1999; 99US-0152024P.
XX	
PA	(BIOT ) BIOTRON INC.
XX	
PI	Wesley D;
DR	WPT; 2001-235091/24.
XX	
DR	N-PSDB; AAP57270.
XX	
PT	Novel Ret ligand polypeptide useful for suppressing growth of a tumor cell that expresses Ret and for modulating Ret signal transduction involving a cell expressing Ret polypeptide or Ret ligand polypeptide.
XX	
PS	Claim 13; Fig 3; 76pp; English.

The invention relates to mouse and human Ret ligand 5 (RetL5) polypeptides. The RetL5 polypeptides can be expressed by standard recombinant methodology. The RetL5 when bound to Ret, acts as a dimerization or autophosphorylation activator. The polypeptides and their antibodies are useful for stimulating growth of or limiting damage to, Ret expressing tissue in a subject, for suppressing growth of a tumor cell that expresses Ret, for modulating the Ret signal transduction involving a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion proteins containing RetL5 and antibodies are useful for stimulating renal tissue growth and/or survival, supporting renal function and minimizing damage to renal tissue after various insults, particularly for treating acute renal failure, acute nephritis, chronic renal failure, nephrotic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury and trauma. The compounds are also useful for treating conditions such as neural degeneration where neural growth and regeneration are desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, a well as motor neuron disease, demyelinating disease, bacterial diseases, viral diseases, and prion diseases including Creutzfeldt-Jakob disease. The compounds are also useful for treating disorders due to damage to neural tissue caused by neoplastic impingement, trauma or cerebrovascular events such as hemorrhage or emboli, and neural disorders such as mental retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral palsy. The present sequence represents the mouse RetL5 polypeptide predicted by visual inspection method.

01-SEP-1999; 99US5-0152024P.  
(BIOJ ) BIOGEN INC.  
Worley D;  
WPI; 2001-235091/24.  
Novel Ret ligand polypeptide useful for suppressing growth of a tumor  
cell that expresses Ret and for modulating Ret signal transduction  
involving a cell expressing Ret polypeptide or Ret ligand polypeptide.  
Example 10; Page 39-40; 76pp; English.

```

Query Match    76.3%; Score 1078; DB 4; Length 277;
Best Local Similarity 87.4%; Pred. No. 1e-92;
Matches 201; Conservative 7; Mismatches 14; Indels 8; Gaps 2

```

Y	27	GSASSTFGNRCVEEAECTADBOCOORSEVYAOQICGRR---GWRGGSCVRSRCHRLR	83
b	16	GSASFTIGNRCUDAAEBCACTABRCOOLSERVARCIGRAAPGGRPGGGCVRSCRCRALR	75
Y	84	RFFARGPPALTHALLFGCCEGPPACAERRRTPAPACFLSGSPOLAPSSPLKPLDRCCRSR	143
b	76	RFFARGPPALTHALLFGCCEGSSACAERRRTPAPACFLSGPGLVUPPSCLBLERCRERSL	135
b	144	CPRLUFQAQSCAPAGFSDGCGPEEGPRCLRAYAGIIVGTVTPNLLDNVARVALPWC	203
b	136	CPRLUFQAQSCAPAGSDRDCEGCPRLAYAGIIVGTVTPNLLDNVARVALPWC	195
Y	204	BSAGNRECECAFRKLFTRNCFLDGA1QAFSSQSPVTLQDOWNPYNAQGQ-----	253
b	196	BSAGNRECECAFRKLFTRNCFLDGA1QAFSLQPSLQD----OrAQGQ-----	240

AB62107  
 D AAB62107 standard; protein; 476 AA.  
 X  
 C  
 AAB62107;  
 X  
 T  
 29-MAY-2001 (first entry)  
 X  
 X  
 X  
 Murine RetLS/human IgG Fc fusion protein.  
 Ret Ligand 5; RetLS; autophosphorylation; tumour; renal; nephrotopic;  
 Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;  
 vulnerable; nootropic; anti-HIV; neuroprotective; antibiotic;  
 cerebroprotective; hematopoietic; antiinflammatory; antiviral; neuroleptic;  
 IgG; fusion protein; GDNP; neiblastin; NBN.

PN WO200116169-A2.  
XX  
XX  
PD 08-MAR-2001.  
XX  
PP 01-SEP-2000; 2000WO-US024111.  
XX

XX  
 KW Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotoxic;  
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse;  
 KW cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.  
 XX  
 OS Mus sp.  
 XX WO200116169-A2.  
 XX 08-MAR-2001.  
 XX PP 01-SEP-2000; 2000WO-US024111.  
 XX PR 01-SEP-1999; 99US-0152024P.  
 XX PA (BIOJ ) BIOPEN INC.  
 PT Worley D;  
 XX DR WPI; 2001-235091/24.  
 DR N-PSDB; ABL57273.  
 XX PT Novel Ret ligand polypeptide useful for suppressing growth of a tumor  
 PT cell that expresses Ret and for modulating Ret signal transduction  
 PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.  
 PS Disclosure; Fig 8; 76pp; English.

The invention relates to mouse and human Ret ligand 5 (RetL5),  
 CC polypeptides. The RetL5 polypeptides can be expressed by standard  
 CC recombinant methodology. The RetL5 when bound to Ret, acts as a  
 CC dimerization or autoprophosphorylation activator. The polypeptides and their  
 CC antibodies are useful for stimulating growth of or limiting damage to,  
 CC Ret expressing tissue in a subject, for suppressing growth of a tumour  
 CC cell that expresses Ret, for modulating Ret signal transduction involving  
 CC a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion  
 CC proteins containing RetL5 and antibodies are useful for stimulating renal  
 CC tissue growth and/or survival, supporting renal function and minimizing  
 CC damage to renal tissue after various insults, particularly for treating  
 CC acute renal failure, acute nephritis, chronic renal failure, nephrotic  
 CC syndrome, renal tubule defects, kidney transplant, toxic injury, hypoxic  
 CC injury and trauma. The compounds are also useful for treating conditions  
 CC such as neural degeneration where neural growth and regeneration are  
 CC desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's  
 CC disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as  
 CC motor neuron disease, demyelinating disease, bacterial diseases, viral  
 CC diseases, and prion diseases including Creutzfeldt-Jakob disease. The  
 CC compounds are also useful for treating disorders due to damage to neural  
 CC tissue caused by neoplastic impingement, trauma or cerebrovascular events  
 CC such as hemorrhage or emboli, and neural disorders such as mental  
 CC retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral  
 CC palsy. The present sequence represents an alternatively spliced mouse  
 XX RetL5 polypeptide  
 SQ Sequence 260 AA;

Query Match 76.1%; Score 1075.5; -DB 4; Length 260;  
 Best Local Similarity 89.6%; Pred. No. 6.5e-92; Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;  
 Db 27 GSASSTEGNRCEVAEAACTADEOQOLRSVYAQCLGRA--GWRGPSCVRSCRRALR 83  
 Db 16 GSASFDTDGNRCVDAEACTADERCOQLRSVYVARCIGRAAPGGRGPAGCVRSCRRALR 75  
 Qy 84 RFFPAGGPPALTHAFLFCGEGPACHERROTAPACAFSGQQLAPPSCIKPLDCRERR 143  
 Db 76 RFFFARGGPPLTHAFLFCGEGSACERROTAPACAFSGQQLAPPSCIKPLDCRERR 135  
 Qy 144 CRPRLFQFQASCAPAPSGSRDGCPSBEGPGPRCLRAYAGLVGVTVTNYLDNVSARVAPWGCG 203  
 Db 136 CRPRLFQFQASCAPAPSGSRDGCPSBEGPGPRCLRAYAGLVGVTVFNPYLDNVSARVAPWGCG 195  
 XX RESULT 6  
 XX ABB0214  
 ID ABB0214 standard; protein; 260 AA.  
 XX ABB0214;  
 XX DT 08-JUL-2002 (first entry)  
 DE Mouse GPI-anchored isoform al protein SEQ ID NO:1.  
 XX GFRalpha4; glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor;  
 KW glial cell line derived neurotrophic factor; osteopathic; tumour;  
 KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour;  
 KW medillary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia;  
 KW neuronal disorder; aberrant axonal sprouting.  
 XX OS Mus musculus.  
 XX PN WO2001162795-A1.  
 XX PD 30-AUG-2001.  
 XX PI 14-NOV-2000; 2000WO-F1000994.  
 XX PR 21-FEB-2000; 20000PI-000000394.  
 XX PA (LICE-) LICENTIA LTD.  
 XX Airaksinen M, Sharma M, Poteriaev D, Lindahl M, Timmusk T;  
 PI ROSSI J;  
 XX WPI; 2001-596722/67.  
 DR N-PSDB; ABL51663.  
 XX PT New nucleic acid sequence for manufacturing polypeptides for treating  
 CC endocrine cancers comprises a cDNA encoding a splicing isoform of  
 PR mammalian growth factor receptor (GFR)alpha4.  
 XX PS Claim 9; Fig 18; 143pp; English.  
 CC The present invention describes an isolated and purified cDNA sequence  
 CC encoding a splicing isoform of a mammalian growth factor receptor  
 CC (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic,  
 CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is  
 CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived  
 CC neurotrophic factor (GDNF) family alpha receptor. A GFRalpha4  
 CC polynucleotide sequence can be used for recording GFRalpha4 mediated  
 CC signalling in neurons or endocrine cells such as thyroid calcitonin-  
 CC producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or  
 CC cells from the pituitary intermediate lobe. GFRalpha4 protein and  
 CC polynucleotide sequences can be used for manufacturing polypeptides  
 CC useful for diagnosing and/or treating tumours in parathyroid gland cells,  
 CC adrenal chromaffin cells, cells of pituitary intermediate lobe,  
 CC pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for  
 preventing neuronal death or aberrant axonal sprouting. The present  
 CC sequence represents the mouse GFRalpha 4 protein, designated GPI-anchored  
 XX isoform al, from the present invention  
 SQ Sequence 260 AA;

Query Match 76.1%; Score 1075.5; -DB 4; Length 260;  
 Best Local Similarity 89.6%; Pred. No. 6.5e-92; Matches 198; Conservative 7; Mismatches 13; Indels 3; Gaps 1;  
 Db 27 GSASSTEGNRCEVAEAACTADEOQOLRSVYAQCLGRA--GWRGPSCVRSCRRALR 83  
 Qy 76 RFFFARGGPPLTHAFLFCGEGSACERROTAPACAFSGQQLAPPSCIKPLDCRERR 135  
 Qy 144 CRPRLFQFQASCAPAPSGSRDGCPSBEGPGPRCLRAYAGLVGVTVTNYLDNVSARVAPWGCG 203  
 Db 136 CRPRLFQFQASCAPAPSGSRDGCPSBEGPGPRCLRAYAGLVGVTVFNPYLDNVSARVAPWGCG 195  
 XX

**Db** 16 GSASFTDGNRCVDAEACTADBERCQQLRSEYVYARCLGRAPAGRPGPGGCVRSRRALR 75  
**Qy** 84 RFFARGPAPALTHALFGCGECAERQRQTAPACAFSGQPLAPSCKLKDRCRSRR 143  
**Db** 76 RFFARGPAPALTHALFGCGECAERQRQTAPACAFSGQPLAPSCKLKDRCRSRL 135  
**Qy** 144 CRPLPFAFQASCAPAPGSRDGGCPEEGPRCLRAYAGLVGTWTTPNVLNDNSARVAPWGC 203  
**Db** 136 CRPLLFAQASCAPAPGSRDGGCPEEGPRCLRAYAGLVGTWTTPNVLNDNSARVAPWGC 195  
**Qy** 204 EASGNRRECECAFRLKFLTRNCPLDGAIAOFSSQPSVLUQDQ 244  
**Db** 196 AASGNRRECECAFRLKFLTRNCPLDGAIAOFDSLQPSVLUQDQ 236

**RESULT 7**  
**ABB0215**  
**ID** ABB0215 standard; protein; 293 AA.  
**XX**  
**AC** ABB0215;  
**XX**  
**DT** 08-JUL-2002 (first entry)  
**XX**  
**DE** Mouse putative transmembrane isoform a2 protein SEQ ID NO:2.  
**XX**  
**KW** GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytostatic; glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor; glial cell line derived neurotrophic factor; osteopathtic; tumour; neuroprotective; anticonvulsant; neoplasia; endocrine tumour; medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; neuronal disorder; aberrant axonal sprouting.  
**KW** neuronal disorder; aberrant axonal sprouting.  
**OS** Mus musculus.  
**XX**  
**PN** WO200162795-A1.  
**PD** 30-AUG-2001.  
**XX**  
**PP** 14-NOV-2000; 2000WO-FI000994.  
**XX**  
**PR** 21-FEB-2000; 2000FI-00000394.  
**XX**  
**PA** (LICE-) LICENTIA LTD.  
**XX**  
**PI** Airaksinen M, Saarma M, Poteraev D, Lindahl M, Timmusk T;  
**PT** Rossi J;  
**XX**  
**DR** DR N-PSDB; ABIS1670.

**XX**  
**PT** New nucleic acid sequence for manufacturing polypeptides for treating endocrine cancers comprises a cDNA encoding a splicing isoform of mammalian growth factor receptor (GFR)alpha4.  
**XX**  
**PS** Claim 9; FIG 19B; 143pp; English.

The present invention describes an isolated and purified cDNA sequence encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic, osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived neurotrophic factor (GDNF) family alpha receptor. A GFRalpha4 polynucleotide sequence can be used for recording GFRalpha4 mediated signalling in neurons or endocrine cells such as thyroid calcitonin-producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or cells from the pituitary intermediate lobe. GFRalpha4 protein and polynucleotid sequences can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, adrenal chromaffin cells, cells of pituitary intermediate lobe, neoplasia, endocrine tumours, medullary thyroid carcinoma and pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for preventing neuronal death or aberrant axonal sprouting. The present sequence represents the mouse GFRalpha 4 protein, designated putative

**CC** transmembrane isoform a2, from the present invention  
**XX**  
**SQ** Sequence 293 AA;

**Query Match** 76.1%; **Score** 1075.5; **DB** 4; **Length** 293; **Best Local Similarity** 89.6%; **Pred.** No. 7; 4e-92; **Indels** 3; **Gaps** 1; **Matches** 198; **Conservative** 7; **Mismatches** 13; **DB** 16 GSASFTDGNRCVDAEACTADBERCQQLRSEYVYARCLGRAPAGRPGPGGCVRSRRALR 75  
**Qy** 27 GSASFTDGNRCVDAEACTADBERCQQLRSEYVQCLGRA--GWGGGSCVRSRRALR 83  
**Db** 16 GSASFTDGNRCVDAEACTADBERCQQLRSEYVYARCLGRAPAGRPGPGGCVRSRRALR 75  
**Qy** 84 RFFARGPAPALTHALFGCGECAERQRQTAPACAFSGQPLAPSCKLKDRCRSRL 143  
**Db** 76 RFFARGPAPALTHALFGCGECAERQRQTAPACAFSGQPLAPSCKLKDRCRSRL 135  
**Qy** 144 CRPLPFAFQASCAPAPGSRDGGCPEEGPRCLRAYAGLVGTWTTPNVLNDNSARVAPWGC 203  
**Db** 136 CRPLLFAQASCAPAPGSRDGGCPEEGPRCLRAYAGLVGTWTTPNVLNDNSARVAPWGC 195  
**Qy** 204 EASGNRRECECAFRLKFLTRNCPLDGAIAOFSSQPSVLUQDQ 244  
**Db** 196 AASGNRRECECAFRLKFLTRNCPLDGAIAOFDSLQPSVLUQDQ 236

**RESULT 8**  
**ABB62104**  
**ID** ABB62104 standard; protein; 264 AA.  
**XX**  
**AC** ABB62104;  
**XX**  
**DT** 29-MAY-2001 (first entry)  
**XX**  
**DB** Mouse RetL5 polypeptide.  
**XX**  
**PT** Ret ligand 5; RetL5; autophosphorylation; tumour; renal; nephrotropic; Alzheimer's disease; Parkinson's disease; Huntington's disease; mouse; vulnerable; nootropic; anti-HIV; neuroprotective; antibacterial; cerebroprotective; hemostatic; antiinflammatory; antiviral; neuroleptic.  
**XX**  
**OS** Mus sp.  
**XX**  
**PH** Key  
**PT** Peptide  
**FT** 1..21  
**FT** /note= "signal peptide"  
**FT** Protein  
**FT** 22..264  
**FT** /note= "mature protein"  
**XX**  
**PN** WO200116169-A2.  
**PD** 08-MAR-2001.  
**XX**  
**PP** 01-SEP-2000; 2000WO-US024111.  
**XX**  
**PR** 01-SEP-1999; 99US-0152024P.  
**XX**  
**PA** (BIOJ ) BIOPEN INC.  
**XX**  
**PT** Worley D;  
**XX**  
**DR** WPI; 2001-235091/24.  
**XX**  
**PS** N-PSDB; AAB57271.

**XX**  
**PT** Novel Ret ligand polypeptide useful for suppressing growth of a tumor cell that expresses Ret and for modulating Ret signal transduction PT involving a cell expressing Ret polypeptide or Ret ligand polypeptide.  
**XX**  
**Claim 13; Fig 4; 76pp; English.**

The invention relates to mouse and human Ret ligand 5 (RetL5) polypeptides. The RetL5 polypeptides can be expressed by standard recombinant methodology. The RetL5 when bound to Ret, acts as a dimerization or autophosphorylation activator. The polypeptides and their

antibodies are useful for stimulating growth or limiting damage to, Ret expressing tissue in a subject, for suppressing growth of a tumour cell that expresses Ret, for modulating Ret signal transduction involving a cell expressing the Ret polypeptide. The RetL5 polypeptides, fusion proteins containing RetL5 and antibodies are useful for stimulating renal tissue growth and/or survival, supporting renal function and minimizing damage to renal tissue after various insults, particularly for treating acute renal failure, acute nephritis, chronic renal failure, nephrotic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury and trauma. The compounds are also useful for treating conditions such as neural degeneration where neural growth and regeneration are desirable, e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, as well as motor neuron disease, demyelinating disease, bacterial diseases, viral diseases, and prion diseases including Creutzfeld-Jakob disease. The compounds are also useful for treating disorders due to damage to neural tissue caused by neoplastic impingement, trauma or cerebrovascular events such as hemorrhage or emboli, and neural disorders such as mental retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral palsy. The present sequence represents the mouse RetL5 polypeptide predicted from DSW300 sequence by GENSCAN/GENE ALEX

SQ Sequence 264 AA:

Query Match	72.8%	Score	1028.5;	DB	4;	Length	264;		
Best Local Similarity	86.9%;	Pred. No.	1.6e-87;						
Matches	192;	Conservative	7;	Mismatches	13;	Indels	9;	Gaps	2;
OY	27	GSASSTEGNRVCEAYEAFACTADEQQCOLRSYVAQCLGRA--GHEGPAGCVRSRKRRAIR	83						
Db	16	GSASTSTDGRCVDAEFACTADBERCQDQRSEVARYTIGRAAAGPGRGGCVRSSRRAIR	75						
OY	84	RFPARGPPALTHALIFCGCGPACERRQTFAPACFAPGCPQLAPSPCKPLDRGERSRR	143						
Db	76	RFFARGGPALTHALIFCGCGSACERRQTFAPACFAPGCPQLAPSPCKPLERCRSLR	135						
OY	144	CRPRIFAFQASCAPAPGSRDGCPCBEGPGRPLRAVAGLVLGVTVTPNLYDNARYARVAPWCGC	203						
Db	136	CR-----CASCAPAPGSRDGCPCBEGPGRPLRAVAGLVLGVTVTPNLYDNARYARVAPWCGC	189						
OY	204	EASGNRREECEAFRLFLTRNPCLQGAIQARDSSPPSVLDDQ	244						
Db	190	AASGNRREECEAFRLFLTRNPCLQGAIQARDSSPPSVLDDQ	230						

RESULT 9  
 AAV42771  
 ID AAV42771 standard; protein; 340 AA.  
 XX  
 AC AAV42771;  
 XX  
 DT 05-JAN-2000 (first entry)  
 DE Marine glial derived neurotrophic factor receptor-alpha-X protein.  
 DE  
 KW Glial derived neurotrophic factor-alpha-X; GFR-alpha-X; neural cell; survival; function; nervous system; signalling; diagnosis; treatment; neurological disorder; sensory disorder; Dejerine-Roussy syndrome; contralateral anaesthesia; eating disorder; obesity; motor disorder; Parkinson's disease; amyotrophic lateral sclerosis; ALS; cognitive disorder; Alzheimer's disease.  
 KW  
 OS Mus sp.  
 XX  
 FH Key location/Qualifiers  
 FT Misc-difference 201 /note= "Encoded by ANG"  
 FT Misc-difference 217 /note= "Encoded by AAN"  
 FT Misc-difference 340 /note= "Encoded by TG"  
 PN WQ9950298-Al.

Claim 1; Fig 1; 100pp; English.  
This sequence represents murine glial derived neurotrophic factor.

receptor-glia-alph- $\alpha$ -X (GFR-alpha-X) protein. GFR-alpha-X is a fourth member of the GFR-alpha family of receptors. The cDNA was identified in a positional cloning process in which the mouse mangafy locus was being sequenced to identify genes involved in obesity. The GFR-alpha-X protein binds to neurotrophic factors such as GDNF (glial cell line-derived neurotrophic factor) and/or NTN (neurturin), and mediates signalling within cells expressing the GFR-alpha-X protein. GFR-alpha-X, like the other three members of the GFR-alpha family (GFR-alpha-1, -2, and -3), transmits a signal to the interior of a cell by activation of the RET protein tyrosine kinase signalling pathway. Neurotrophic factors promote survival and function of neural cells of both the central and peripheral nervous systems. Modulation of GFR-alpha-X activity can result in modulation of the neurotrophic factor-initiated cell function. Probes and/or primers derived from GFR-alpha-X cDNA, and antibodies against the protein are used to detect the presence of GFR-alpha-X nucleic acids or protein and can be used in the diagnosis and treatment of a variety of neurological disorders, including sensory and motor disorders (e.g., Dejerine-Roussey syndrome, contralateral anesthesia, and certain eating disorders), motor disorders (e.g., Parkinson's disease, amyotrophic lateral sclerosis), and cognitive disorders (e.g., Alzheimer's disease). In addition, compounds which bind to GFR-alpha-X may be used to modulate the activity of the protein.

**Sequence 340 AA;**  
**SQ**

Query	Match	Best Local Similarity	Score	DB	Length	340;
Qy	GSASSTEGNRCTVEAACTA	68.2%	927;	2;	Length	340;
Db	Matches 180; Conservative 10; Mismatches 28; Indels 46; Gaps 3;					
Qy	GSASSTEGNRCTVEAACTA	68.2%	927;	2;	Length	340;
Db	19 GSASFDTGNRCVDAEACTADBRQCQSERVYVARCQHRAAPGGRPQPGCVRSRCSRPLR	83				
Qy	84 RFPARSGPALTIALLGCGCEGACARROQFAPAFSGQQLAPSCLAFLDRERSRR	83				
Db	79 RFFPARGPALTHALLGCGBEASCARRRQFTPAPAFSGQGLPVPSCLLPLERRSRL	78				
Qy	144 CPRFLIAFOQASCAPAGSRSRGDCPEEGPQRPLRVAAGLVGTWTPNTLDNYSARVAVWCGC	143				
Db	139 CEPRLIAFOQASCAPAGSRSRGDCPEEGPQRPLRVAAGLVGTWTPNTLDNYSARVAVWCGC	198				
Qy	204 EASGNRREEBECAFRK-----LTFRN-----	223				
Db	199 AAXWKPARMRSLSPLQYXGTPAWWRGGGGPGEPRMSVAQSKLPGPMLWPSHHVWCGRW	258				
Qy	224 --PCIDGAQAFDSQPSVQDQ	244				
Db	259 TVCTCDDGATQAFDSLQPSVLQDQ	282				

ID	ABB09217	standard; protein; 269 AA.
XX		
XX	AC	133 RLLAQVQCTPPAPSAPDGCLLDDGARCLRAYAGLVGTAVPNNYDVNSARVAPWCDGAS 192
XX	ACB09217;	
XX	08-JUL-2002 (first entry)	
XX		
DT		
DE	Human GPI-anchored isoform a protein SEQ ID NO:4.	
XX		
KW	GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosolic; glycolyl-phosphate-linked inositol-linked GDNF family alpha-receptor; glial cell line derived neurotrophic factor; osteopathic; tumour; neuroprotective; anticonvulsant; neoplasia; endocrine tumour; medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; neuronal disorder; aberrant axonal sprouting.	
KW	Homo sapiens.	
OS		
XX		
PN	WO20162795-A1.	
XX		
PD	30-AUG-2001.	
XX		
PF	14-NOV-2000; 2000WO-FI000994.	
XX		
PR	21-FEB-2000; 2000FI-0000394.	
XX		
PA	(LICB-) LICENTIA LTD.	
XX		
PI	Airaksinen M, Saarma M, Poteraev D, Lindahl M, Timmusk T;	
PT	Rossi J;	
XX		
DR	WPI; 2001-596722/67.	
XX		
PS	N-PSDB; ABL51672.	
XX		
PT	New nucleic acid sequence for manufacturing polypeptides for treating endocrine cancers comprises a cDNA encoding a splicing isoform of mammalian growth factor receptor (GFR)alpha4.	
XX		
CC	Claim 9; Fig 21B; 143pp; English.	
CC	The present invention describes an isolated and purified cDNA sequence encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytosolic, osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4 polynucleotide sequence can be used for recording GFRalpha4 mediated signalling in neurons or endocrine cells such as thyroid calcitonin-producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or cells from the pituitary intermediate lobe. GFRalpha4 protein and polynucleotide sequences can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, adrenal chromaffin cells, cells of pituitary intermediate lobe, neoplasia, endocrine tumours, medullary thyroid carcinoma and pheochromocytoma, parathyroid hyperplasia, neuronal disorders or preventing neuronal death or aberrant axonal sprouting. The present sequence represents the human GFRalpha 4 protein, designated GPI-anchored isoform a, from the present invention	
CC	XX	
CC	SQ Sequence 269 AA;	
Query	Match 65.1%; Score 920.5; DB 4; Length 269; Best Local Similarity 78.3%; Pred. No. 1.9e-77; Matches 173; Conservative 11; Mismatches 34; Indels 3; Gaps 1;	
Qy	27 GSASSTGNRCTEAAACTADQSCQPRRSYQAQCLRGAGWGRGPSCVRSRRAUFRP 86	
Db	16 GRASSVGNGRCVDAEACTADQCRQRRSEYQAQCGEPRAKERRAKFP 72	
Qy	87 ARGPPALTHALLFCGCGPACARRRTPAPACGSPQLAPPSCLUKDLRGRSRRCRP 146	
Db	73 ARCPPLAHLFCPCAGPACARRRTPVSPCAFSGGPGPAPSPCLPFLNRCRSVRCP 132	
Qy	147 RLFAPQSCAPARGSDQCGPEEGPRCIRAYAGLVGTWTPNLDNTSARVAPWCGEAS 206	
Db	133 RLLAQVQCTPPAPSAPDGCLLDDGARCLRAYAGLVGTAVPNNYDVNSARVAPWCDGAS 192	RESULT 11
Qy	207 GNRRECEAFRKPFTRNPQLDGAIQAFDSQQPSVLQDQWNP 247	AAB62105
Db	193 GNRRECEAFRKPFTRNPQLDGAIQAFDSQQPSVLQDQWNP 233	ID AAB62105 standard; protein; 282 AA.

CC such as hemorrhage or emboli, and neural disorders such as mental retardation, autism, fetal alcohol syndrome, Down's syndrome and cerebral palsy. The present sequence represents the human RetL5 polypeptide

SQ Sequence 282 AA;

Query Match 64.7%; Score 914.5; DB 4; Length 282;  
Best Local Similarity 74.6%; Pred. No. 7.4e-77; Matches 173; Conservative 15; Mismatches 41; Indels 3; Gaps 1;

Qy 27 GSASSTEGNRVEAACTAEDQOQLRSEVACQCLGRAGRGPGSCVSRCCRRLRFP 86  
Db 16 GSASSVGNRCVDAEACTADARCORLSEYVAQCIGRA--AQGCPRACRRLRFP 72

Qy 87 ARGPPALTHAILFCGGPGACERRQTAPACASGSPOLAPSCLPKDRCSRRCR 146  
Db 73 ARGPPALTHAILFCGGPGACERRQTAPACASGSPOLAPSCLPKDRCSRRCR 132

Qy 147 RLPAFQASCADAPGSRDGCPRGGPRLRAYAGLVGVNVBNYLDNSARVAPWGCEAS 206  
Db 133 RLLAFQVSCTTAPSADGCLDQGARCLRAYAGLVGVNVBNYLDNSARVAPWCDGAS 192

Qy 207 GNRERBCEAFKFLTRNPLCQGAIAOFDSSPSVLDQWMPYQNAQAYEA 258  
Db 193 GNRERDCEAFGLFTRNRCLGAIQAFASGWEPVILDLQNLNQGDPEHSLIQA 244

RESULT 12

ABB0218 ID ABB0218 standard; protein; 299 AA.

XX ABB0218;

AC XX

DT 08-JUL-2002 (first entry)

DE Human putative GPI-anchored isoform b protein SEQ ID NO:5.

XX GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosatic; KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor; KW glial cell line derived neurotrophic factor; osteopathic; tumour; KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour; KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; KW neuronal disorder; aberrant axonal sprouting.

OS Homo sapiens.

PN WO200162795-A1.

PD 30-AUG-2001.

XX 14-NOV-2000; 2000WO-FI000994.

XX 21-FEB-2000; 2000FI-00000394.

PA (LICE-) LICENTIA LTD.

PT Airaksinen M, Saarma M, Poteriaev D, Lindahl M, Timmusk T; Rossi J; DR WPI; 2001-596722/67.

DR N-PSDB; ARIUS1673.

XX New nucleic acid sequence for manufacturing polypeptides for treating PT endocrine cancers comprises a cDNA encoding a splicing isoform of PT mammalian growth factor receptor (GFR)alpha4.

XX Claim 9; FIG 22B; 143pp; English.

CC The present invention describes an isolated and purified cDNA sequence CC encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic, CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived

CC neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4 polymucleotide sequence can be used for recording GFRalpha4 mediated signalling in neurons or endocrine cells such as thyroid calcitonin-producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or cells from the pituitary intermediate lobe. GFRalpha4 protein and polynucleotide sequences can be used for manufacturing polypeptides useful for diagnosing and/or treating tumours in parathyroid gland cells, adrenal chromaffin cells, cells of pituitary intermediate lobe, neoplasia, endocrine tumours, medullary thyroid carcinoma and pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for preventing neuronal death or aberrant axonal sprouting. The present sequence represents the human GFRalpha 4 protein, designated putative GPI-anchored isoform b, from the present invention.

SQ Sequence 299 AA;

Query Match 54.3%; Score 767.5; DB 4; Length 299;  
Best Local Similarity 62.5%; Pred. No. 4.1e-63; Matches 157; Conservative 10; Mismatches 51; Indels 33; Gaps 3;

Qy 27 GSASSTEGNRVEAACTAEDQOQLRSEVACQCLGRAGRGPGSCVSRCCRRLRFP 86  
Db 16 GSASSVGNRCVDAEACTADARCORLSEYVAQCIGRA--AQGCPRACRRLRFP 72

Qy 87 ARGPPALTHAILFCGGPGACERRQTAPACASGSPOLAPSCLPKDRCSRRCR 145  
Db 73 ARGPPALTHAILFCGGPGACERRQTAPACASGSPOLAPSCLPKDRCSRRCR 132

Qy 146 ----- PRLFAFQASCADAPGSRDGCPRGGPRLRAY 177  
Db 133 ARAAGPWRGMGRGLSPAHRRPAAOASPFOLPSLGLVHPMSAOPRPLLPGAFGRPLPARLRGP 192

Qy 178 AGL-VGTWTPNLYNDNSARVAPWGCEASGNRREBCEAFKFLTRNPLDGAQAFQSS 236  
Db 193 RGVPAGTAVPNYDVNDNSARVAPWCDGASGNRREBCEAFGLFTRNRCLGATQAFASG 252

Qy 237 QPSVHQDQWNP 247  
Db 253 WPPVLLDQLNP 263

RESULT 13

ABB0219 ID ABB0219 standard; protein; 182 AA.

XX ABB0219;

AC XX

DT 08-JUL-2002 (first entry)

DE Human putative soluble isoform c protein SEQ ID NO:6.

XX GFRalpha4; glycosyl-phosphatidylinositol; GPI; GDNF; cytosatic; KW glycosyl-phosphatidylinositol-linked GDNF family alpha-receptor; KW glial cell line derived neurotrophic factor; osteopathic; tumour; KW neuroprotective; anticonvulsant; neoplasia; endocrine tumour; KW medullary thyroid carcinoma; pheochromocytoma; parathyroid hyperplasia; KW neuronal disorder; aberrant axonal sprouting.

OS Homo sapiens.

PN WO200162795-A1.

PD 30-AUG-2001.

XX 14-NOV-2000; 2000WO-FI000994.

XX 21-FEB-2000; 2000FI-00000394.

PA (LICE-) LICENTIA LTD.

PT Airaksinen M, Saarma M, Poteriaev D, Lindahl M, Timmusk T; Rossi J; DR WPI; 2001-596722/67.

DR N-PSDB; ARIUS1673.

XX New nucleic acid sequence for manufacturing polypeptides for treating PT endocrine cancers comprises a cDNA encoding a splicing isoform of PT mammalian growth factor receptor (GFR)alpha4.

XX Claim 9; FIG 22B; 143pp; English.

CC The present invention describes an isolated and purified cDNA sequence CC encoding a splicing isoform of a mammalian growth factor receptor (GFR)alpha4, or its fragments. GFRalpha4 sequences have cytostatic, CC osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4 is CC a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived

DR	WPI; 2001-596722/67.
XX	N-PSDB; ABL51674.
PT	New nucleic acid sequence for manufacturing polypeptides for treating
PT	endocrine cancers comprises a cDNA encoding a splicing isoform of
PT	mammalian growth factor receptor (GFR)alpha4.
XX	
PS	Claim 9; Fig 23B; 143pp; English.
XX	
CC	The present invention describes an isolated and purified cDNA sequence
CC	encoding a splicing isoform of a mammalian growth factor receptor
CC	osteopathic, neuroprotective and anticonvulsant activities. GFRalpha4
CC	a glycosyl-phosphatidylinositol (GPI)-linked glial cell line-derived
CC	neurotrophic factor (GDNF) family alpha-receptor. A GFRalpha4
CC	polynucleotide sequence can be used for recording GFRalpha4 mediated
CC	signalling in neurons or endocrine cells such as thyroid calcitonin-
CC	producing C-cells, parathyroid gland cells, adrenal chromaffin cells, or
CC	cells from the pituitary intermediate lobe. GFRalpha4 protein and
CC	polynucleotide sequences can be used for manufacturing polypeptides
CC	useful for diagnosing and/or treating tumours in parathyroid gland cells,
CC	adrenal chromaffin cells, cells of pituitary intermediate lobe,
CC	neoplasia, endocrine tumours, medullary thyroid carcinoma and
CC	pheochromocytoma, parathyroid hyperplasia, neuronal disorders or for
CC	preventing neuronal death or aberrant axonal sprouting. The present
CC	sequence represents the human GFRalpha 4 protein, designated putative
CC	solute isoform C, from the present invention
XX	
SQ	Sequence 182 AA;
Query Match	46.0%; Score 649.5; DB 4; Length 182;
Best Local Similarity	75.8%; Pred. No. 2.3e-52;
Matches	122; Conservative 10; Mismatches 26; Indels 3; Gaps 1;
QY	27 GSASSTEGNRVCVEAECTADBDQCQQLRSEVVAQCLGRAGRAGRNGRPGLGSCVRSLRARRLRRFP 86
Db	16 GSASSVGNRVCDAEACTADBDQCQQLRSEVVAQCLGRAGRAGRNGRPGLGSCVRSLRARRLRRFP 72
Qy	87 ARGPPLTHALLFGCGRGPAACERRROTFAAACAFSGPQLRPPSCLKPLDCRSRSRRCR 146
Db	73 ARGPPLTHALLFGCGRGPAACERRROTFAAACAFSGPQLRPPSCLKPLDCRSRSRRCR 132
Qy	147 RLFARQASCAPAPGSRDGCPERGGPRCIRAVAGLVGVTVTP 187
Db	133 RLLAFQVSTTAPSPAPGCLLQDQGARCLRAYAGLVGVSPQAP 173
RESULT 14	
ABB0216	
ID	ABB0216 standard; protein; 190 AA.
AC	ABB0216;
XX	
DT	08-JUL-2002 (first entry)
XX	
DE	Mouse secreted isoform a3/4 protein SEQ ID NO:3.
XX	
QY	27 GSASSTEGNRVCVEAECTADBDQCQQLRSEVVAQCLGRAGRAGRNGRPGLGSCVRSLRARRLRRFP 83
Db	16 GSASSTEGNRVCDAEACTADBDQCQQLRSEVVAQCLGRAGRAGRNGRPGLGSCVRSLRARRLRRFP 75
Qy	84 RFFARGPPLTHALLFGCGRGPAACERRROTFAAACAFSGPQLRPPSCLKPLDCRSRSR 143
Db	76 RFFARGPPLTHALLFGCGRGPAACERRROTFAAACAFSGPQLRPPSCLKPLDCRSRSR 135
Qy	144 CRPRLIFQAFQACAPAGSROCGCPCEGGRC-LRAYAGLVGVTVTPYLNVASVARAWCG 202
Db	136 CRV-----CRAG---RAGPLTRVRAARAGPVLSRPHAL---PRPAPATA 174
Qy	203 CBASGAR 209
Db	175 ARRRGAR 181
RESULT 15	
ABB05369	
ID	ABB05369 standard; protein; 132 AA.
XX	
AC	ABB05369;
XX	
DT	12-SEP-2001 (first entry)
XX	
PH	Key Location/Qualifiers
FT	Misc-difference 85 /notes= "encoded by CGC"
FT	Misc-difference 138 /notes= "encoded by TGC"
FT	Misc-difference 139 /notes= "encoded by GTG"

Search completed: January 26, 2005, 13:12:23  
 Job time : 160 Secs

DE Mouse Gdnf family receptor alpha 4 transmembrane isoform protein.  
 XX KW  
 KW wound healing; cytostatic; antiinflammatory; immunoregulatory; tissue integrity;  
 KW Gdnf family receptor alpha 4 transmembrane isoform; cell trafficking;  
 XX therapy; Gfra4; secreted protein;  
 OS Mus sp.  
 XX  
 PN WO200148192-A1.  
 XX PD  
 XX 05-JUL-2001.  
 XX PP  
 XX 21-DEC-2000; 2000WO-NZ000256.  
 PR 23-DEC-1999; 99US-0171678P.  
 PR 28-NOV-2000; 2000US-00724864.  
 XX PA  
 (GENE-) GENESIS RES & DEV CORP LTD.  
 XX PT  
 Watson JD, Murison JG;  
 XX DR  
 WPI; 2001425665/45.  
 N-PSDB; AAU10139.

XX  
 PT Novel isolated polypeptide useful to isolate corresponding interacting  
 PT proteins or other compounds, to quantitatively determine levels of  
 PT interacting proteins or other compounds, and as therapeutic target.  
 XX  
 PS  
 Claim 6; Page 93; 101pp; English.

XX  
 CC The patent discloses novel polynucleotides and their corresponding  
 CC proteins which play a major role in induction of growth, cell migration  
 CC and proliferation, cell-cell interaction and the differentiation of  
 CC tissue-specific cells. These proteins are important in the maintenance of  
 CC tissue integrity and thus are important in wound healing. They are useful  
 CC in various assays to determine the biological activity, to raise  
 CC antibodies, to isolate corresponding interacting proteins or other  
 CC compounds, to quantitatively determine levels of interacting proteins or  
 CC other compounds, and as therapeutic target in a whole range of disease  
 CC states. Compositions comprising the novel proteins of the invention are  
 CC useful for treating mammalian disorders. Polynucleotides of the invention are  
 CC are useful in genome and physical mapping, in positional cloning of  
 CC genes, to tag or identify an organism or its reproductive material (as  
 CC non-disruptive tags for marking organisms), and for the diagnosis and  
 CC treatment of mammalian diseases which is the consequence of inappropriate  
 CC expression of kinase genes. They are useful for promoting immune response  
 CC as part of a vaccine or anti-cancer treatment, as target for cancer  
 CC treatment, as immunoregulatory and anti-inflammatory molecule, as  
 CC diagnostic for specific types of cancer and for development of an anti-  
 CC cancer treatment, and as a target for antagonists in the treatment of  
 CC diseases such as asthma and allergy. They are also useful to inhibit or  
 CC enhance the activity of the soluble molecule that binds proteins of the  
 CC invention, for tissue and neural regeneration, to promote or block cell  
 CC trafficking, and as anti-inflammatory and/or vaccine adjuvant. The  
 CC present sequence is mouse Gdnf family receptor alpha 4 (Gfra4)  
 CC transmembrane isoform  
 XX  
 Sequence 1132 AA;

Query Match 36.4%; Score 515; DB 4; Length 132;  
 Best Local Similarity 94.0%; Preq. No. 5.6e-40; 1;  
 Matches 94; Conservative 1; Mismatches 5; Indels 0; Gaps 0;  
 Qy 145 RPRLFRAFQASAPARCPGSRDGCPEEGSPRCLAYAGLVLGVWTTPNLYDNYSARVARPGCGC 204  
 Db 9 RPRLFRAFQASAPARCPGSRDGCPEEGSPRCLAYAGLVLGVWTTPNLYDNYSARVARPGCGA 68  
 Qy 205 ASGNRREECEAFRKLFTRNPQLDGAIAOFSSQPSYLDQ 244  
 Db 69 ASGNRREECEAFRKLFTRNPQLDGAIAOFSSQPSYLDQ 108



C;Accession: T10053  
 R;Miner, J.H.; Lewis, R.M.; Sanes, J.R.; Library, November 1997  
 submitted to the EMBL Data Library, November 1997  
 A;Reference number: ZL6923  
 A;Accession: T10053  
 A;Statusus: preliminary; translated from GB/EMBL/DDJB  
 A;Molecule type: mRNA  
 A;Residues: 1-3635 <MIN>  
 A;Cross-references: UNIPROT:Q61001; EMBL:U37501; NID:92599231; PID:92599232  
 C;Genetic:  
 A;Gene: Lama5  
 A;Keywords: basement membrane; cell binding; extracellular matrix  
 F;1888-1939/Domain: laminin-type EGF-like homology <LEG>  
 F;1942-1970/Domain: EGF homology <EGF>  
 Query Match 9.2%; Score 130.5; DB 2; Length 3635;  
 Best Local Similarity 20.4%; Pred. No. 0.013;  
 Matches 65; Conservative 21; Mismatches 97; Indels 135; Gaps 12;  
 Qy 24 CORGSASSTEG-----NRVEAEAC----TRADEOCOOLRSBYA--- 59  
 Db 1763 CARGYIYDTKGLFLRGCVCPCQCHGHSRDLPGSGICVGQCNHTEGDODCERCRGPVSSDP 1822  
 Qy 60 -----OCLGRAGWRGCGSCSVASRCRAALLRPA 87  
 Db 1823 SNPASPVCSPCPCLAVPSNNFADGCVLRNGRTGCLCRPGYAG----ASCERCPAGF 1876  
 Qy 88 RGFPALITHALLFGCGEG-----PACAAERRRQTAPAC----AFSGPQLA 127  
 Db 1877 -NPLVLGssssCOPCSDGPNMIFSDPPLTGACRGCLRHTGPHCERCAPGFGYNALL 1935  
 Qy 128 PESCLK-----PLDRC-----ERSRRRPLRAFO-----ASCAPAP 159  
 Db 1936 PGNCTRCDSCPCTECDCPQSGRCCLKAGVTGQRCCRDCLEGYFGFEOQGCRPCA CGPAA 1995  
 Qy 160 GSRDGCPREG-----GPRCIRAYAGLVGTVTPYLDVNDNSARVAPWCGEASNRR 210  
 Db 1996 KGESECHPOSGQCHQCGPQTCLECAPGYWG-----LPEKGRRQCQPCR 2040  
 Qy 211 EECBAFRKLFTRNPLCDG 228  
 Db 2041 GHCDPPTHGCTCPGLSG 2058

RESULT 3  
 AGRT  
 agrin - rat  
 C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 31-Mar-1993 #sequence\_revision 31-Mar-1993 #text\_change 09-Jul-2004  
 C;Accession: JH0399; A38856  
 R;Rupp, F.; Pavon, D.G.; Magill-Solc, C.; Cowan, D.M.; Scheller, R.H.  
 Neuron 6, 811-823, 1991  
 A;Title: Structure and expression of a rat agrin.  
 A;Title: Structure and expression of a rat agrin.  
 A;Reference number: JH0399; MUID:91222570; PMID:1851019  
 A;Accession: JH0399  
 A;Molecule type: mRNA  
 A;Residues: 1-1779; 1799-1959 <RUP>  
 A;Cross-references: UNIPROT:P22304; GB:MG4780; NID:9202798; PID:AAA40703.1; PID:9202800  
 A;Experimental source: embryonic spinal cord  
 A;Note: it is uncertain whether Met-1, Met-18, or Met-24 is the initiator  
 R;Rupp, F.; Ozcelik, T.; Linial, M.; Peterson, K.; Francke, U.; Scheller, R.  
 J. Neurosci. 12, 3535-3544, 1992  
 A;Title: Structure and chromosomal localization of the mammalian agrin gene.  
 A;Reference number: A38856; MUID:92407628; PMID:1326608  
 A;Accession: A38856  
 A;Molecule type: mRNA  
 A;Residues: 1780-1798 <RU2>  
 A;Cross-references: GB:SA4194  
 C;Comment: This protein mediates the motor neuron-induced aggregation of acetylcholine receptors. It is encoded by variant transcripts labeled as form 3.  
 Y-choline receptor clustering activity.  
 Superfamily: agrin; EGF homology; Kazal protease inhibitor homology; laminin G repeat  
 C;Keywords: alternative splicing; duplication; glycoprotein; neuromuscular junction

RESULT 4  
 T13954  
 MGf6 protein - rat  
 C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
 C;Accession: T13954  
 R;Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Ski, N.; Ohara, O.  
 Genomics 51, 27-34, 1998  
 A;Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs  
 A;Reference number: Z14125; MUID:98160089; PMID:9633030  
 A;Accession: T13954  
 A;Statusus: preliminary; translated from GB/EMBL/DDJB  
 A;Molecule type: mRNA  
 A;Residues: 1-174 <NAK>  
 A;Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:93449293; PID:BA32462.1; PID:9332462  
 A;Experimental source: strain Snrnpa-DanLav brain  
 A;Cross-references: UNIPROT:O88281; EMBL:AB011532; NID:93449293; PID:BA32462.1; PID:9332462

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

## OM protein - protein search, using sw model

Run on: January 26, 2005, 13:15:47 ; Search time 147 Seconds

(without alignments)  
634.100 Million cell updates/sec

Title: US-10-019-337E-9

Perfect score: 1413

Sequence: 1 MLLGAYLRLVINTERPQAVW.....SVLQDQMNQPYQNAGQAKVEA 258

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1608061 seqs, 361289386 residues

Total number of hits satisfying chosen parameters: 1608061

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0\*

Maximum Match 100\*

Listing first 45 summaries

Database : Published Applications AA:\*

1: /cgm2\_6/ptodata/1/pubpaal/US07\_PUBCOMB.pep:\*

2: /cgm2\_6/ptodata/1/pubpaal/PCT\_NEW\_PUB.pep:\*

3: /cgm2\_6/ptodata/1/pubpaal/US06\_PUBCOMB.pep:\*

4: /cgm2\_6/ptodata/1/pubpaal/US06\_PUBCOMB.pep:\*

5: /cgm2\_6/ptodata/1/pubpaal/US07\_NEW\_PUB.pep:\*

6: /cgm2\_6/ptodata/1/pubpaal/US07\_PUBCOMB.pep:\*

7: /cgm2\_6/ptodata/1/pubpaal/US08\_NEW\_PUB.pep:\*

8: /cgm2\_6/ptodata/1/pubpaal/US08\_PUBCOMB.pep:\*

9: /cgm2\_6/ptodata/1/pubpaal/US09\_PUBCOMB.pep:\*

10: /cgm2\_6/ptodata/1/pubpaal/US09\_PUBCOMB.pep:\*

11: /cgm2\_6/ptodata/1/pubpaal/US09\_PUBCOMB.pep:\*

12: /cgm2\_6/ptodata/1/pubpaal/US09\_NEW\_PUB.pep:\*

13: /cgm2\_6/ptodata/1/pubpaal/US10\_PUBCOMB.pep:\*

14: /cgm2\_6/ptodata/1/pubpaal/US10\_PUBCOMB.pep:\*

15: /cgm2\_6/ptodata/1/pubpaal/US10\_PUBCOMB.pep:\*

16: /cgm2\_6/ptodata/1/pubpaal/US10\_PUBCOMB.pep:\*

17: /cgm2\_6/ptodata/1/pubpaal/US11\_NEW\_PUB.pep:\*

18: /cgm2\_6/ptodata/1/pubpaal/US11\_NEW\_PUB.pep:\*

19: /cgm2\_6/ptodata/1/pubpaal/US60\_NEW\_PUB.pep:\*

20: /cgm2\_6/ptodata/1/pubpaal/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query	Match Length	DB ID	Description
1	515	36.4	132	10	US-09-866-050A-709 Sequence 709, App
2	469	33.2	445	16	US-10-673-007-11 Sequence 11, Appl
3	469	33.2	460	17	US-10-872-161-40 Sequence 40, Appl
4	469	33.2	464	9	US-09-388-316-6 Sequence 6, Appl
5	469	33.2	464	14	US-10-357-822-6 Sequence 6, Appl
6	469	33.2	464	16	US-10-673-007-2 Sequence 2, Appl
7	469	33.2	664	9	US-09-388-316-18 Sequence 18, Appl
8	469	33.2	664	14	US-10-357-822-18 Sequence 18, Appl
9	465	32.9	460	14	US-10-241-220-62 Sequence 62, Appl
10	465	32.9	460	17	US-10-872-972-62 Sequence 62, Appl
11	465	32.9	460	17	US-10-872-991-62 Sequence 62, Appl
12	465	32.9	463	14	US-10-555-633-10 Sequence 10, Appl
13	465	32.9	463	14	US-10-155-693-12 Sequence 12, Appl

RESULT 1

US-09-866-050A-709

; Sequence 709, Application US/09866050A

; Publication No. US20030040471A1

; GENERAL INFORMATION:

; APPLICANT: Watson, James D.

; APPLICANT: Strachan, Lorna

; APPLICANT: Sleman, Matthew

; APPLICANT: Onrus, Rene

; APPLICANT: Murison, James G.

; APPLICANT: Kumble, Krishanand D.

; TITLE OF INVENTION: Compositions Isolated From Skin Cells

; TITTLE OF INVENTION: and Methods for Their Use

; FILE REFERENCE: 11000\_101ccu

; CURRENT APPLICATION NUMBER: US/09/866, 050A

; CURRENT FILING DATE: 2001-05-24

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO: 709

; LENGTH: 132

; TYPE: PRT

; ORGANISM: Mouse

; US-09-866-050A-709

; Query Match

; Score 515;

; DB 10;

; Length 132;

; Best Local Similarity

; 94.0%;

; Pred. No. 1e-36;

;保守性

; 94;

; 比较

; 1;

; Mismatches

; 5;

; Indels

; 0;

; Gaps

; 0;

; Matches

; 94;

; Conservative

; 1;

; Mismatches

; 5;

; Indels

; 0;

; Gaps

; 0;

; Sequence 1, Appl

; Sequence 2, Appl

; Sequence 3, Appl

; Sequence 4, Appl

; Sequence 5, Appl

; Sequence 6, Appl

; Sequence 7, Appl

; Sequence 8, Appl

; Sequence 9, Appl

; Sequence 10, Appl

; Sequence 11, Appl

; Sequence 12, Appl

; Sequence 13, Appl

; Sequence 14, Appl

; Sequence 15, Appl

; Sequence 16, Appl

; Sequence 17, Appl

; Sequence 18, Appl

; Sequence 19, Appl

; Sequence 20, Appl

; Sequence 21, Appl

; Sequence 22, Appl

; Sequence 23, Appl

; Sequence 24, Appl

; Sequence 25, Appl

; Sequence 26, Appl

; Sequence 27, Appl

; Sequence 28, Appl

; Sequence 29, Appl

; Sequence 30, Appl

; Sequence 31, Appl

; Sequence 32, Appl

; Sequence 33, Appl

; Sequence 34, Appl

; Sequence 35, Appl

; Sequence 36, Appl

; Sequence 37, Appl

; Sequence 38, Appl

; Sequence 39, Appl

; Sequence 40, Appl

; Sequence 41, Appl

; Sequence 42, Appl

; Sequence 43, Appl

; Sequence 44, Appl

; Sequence 45, Appl

; Sequence 46, Appl

; Sequence 47, Appl

; Sequence 48, Appl

; Sequence 49, Appl

; Sequence 50, Appl

; Sequence 51, Appl

; Sequence 52, Appl

; Sequence 53, Appl

; Sequence 54, Appl

; Sequence 55, Appl

; Sequence 56, Appl

; Sequence 57, Appl

; Sequence 58, Appl

; Sequence 59, Appl

; Sequence 60, Appl

; Sequence 61, Appl

; Sequence 62, Appl

; Sequence 63, Appl

; Sequence 64, Appl

; Sequence 65, Appl

; Sequence 66, Appl

; Sequence 67, Appl

; Sequence 68, Appl

; Sequence 69, Appl

; Sequence 70, Appl

; Sequence 71, Appl

; Sequence 72, Appl

; Sequence 73, Appl

; Sequence 74, Appl

; Sequence 75, Appl

; Sequence 76, Appl

; Sequence 77, Appl

; Sequence 78, Appl

; Sequence 79, Appl

; Sequence 80, Appl

; Sequence 81, Appl

; Sequence 82, Appl

; Sequence 83, Appl

; Sequence 84, Appl

; Sequence 85, Appl

; Sequence 86, Appl

; Sequence 87, Appl

; Sequence 88, Appl

; Sequence 89, Appl

; Sequence 90, Appl

; Sequence 91, Appl

; Sequence 92, Appl

; Sequence 93, Appl

; Sequence 94, Appl

; Sequence 95, Appl

; Sequence 96, Appl

; Sequence 97, Appl

; Sequence 98, Appl

; Sequence 99, Appl

; Sequence 100, Appl

RESULT 2  
US-10-673-007-11  
; Sequence 11, Application US/10673007  
; Publication No. US20040126819A1  
; GENERAL INFORMATION:  
; APPLICANT: Ibanez, Carlos F.  
; APPLICANT: Arumae, Urmias  
; APPLICANT: Sariola, Hanno  
; APPLICANT: Savonto, Petri  
; APPLICANT: Trupp, Miles  
; APPLICANT: Saarma, Mart  
TITLE OF INVENTION: Glial Cell Line-Derived Neurotropic Factor Receptors  
FILE REFERENCE: CEPH0418  
CURRENT APPLICATION NUMBER: US/10/673,007  
CURRENT FILING DATE: 2003-09-26  
PRIORITY APPLICATION NUMBER: US/08/861,990  
PRIORITY FILING DATE: 1997-05-22  
PRIORITY APPLICATION NUMBER: US/08/861,990  
PRIORITY FILING DATE: 1996-11-13  
PRIORITY APPLICATION NUMBER: 60/006,619  
PRIORITY FILING DATE: 1995-11-13  
PRIORITY APPLICATION NUMBER: 60/015,767  
PRIORITY FILING DATE: 1996-04-16  
PRIORITY APPLICATION NUMBER: 60/021,965  
PRIORITY FILING DATE: 1996-06-27  
PRIORITY APPLICATION NUMBER: 60/020,638  
PRIORITY FILING DATE: 1996-06-27  
PRIORITY APPLICATION NUMBER: 60/020,639  
PRIORITY FILING DATE: 1996-06-27  
NUMBER OF SEQ ID NOS: 11  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 11  
LENGTH: 445  
TYPE: PRT  
ORGANISM: Rattus sp.  
US-10-673-007-11

Query Match 33.2%; Score 469; DB 16; Length 445;  
Best Local Similarity 43.0%; Pred. No. 3.4e-32;  
Matches 89; Conservative 33; Mismatches 79; Indels 6; Gaps 3;

Qy 29 ASSTEGNRVCVAEAACTADEBQCQLRSYVAAQCLGRAGWGRGPGCVSRCCRARRRFFAR 88  
Db 149 AVSTKSNHCLDAAKACNACNNDCKKLRRSYVISIONREIS--PTERCRNRKCHALKRQFDR 206  
Qy 89 GPPALTAHLIFCGCEGGPACAERROTAPACASGPQQLAPPSPKLKDRCERSRRCPRL 148  
Db 207 VPSETYRMILFCSCODQACDERRTOLPLSCSYDKE--KPNCLDLRSLCRTDHLCRSRL 264  
Qy 149 FAFOASCAPAPGSRDGCPEEGPRCLRAYLAGLVGTWTPNYLDN--VSARVAPWCGGEAS 206  
Db 265 ADFHANCRAASYRTITSCADNKGACTSSAYGMIGFDWMPNVDNSPQTIVSPWCNGRS 324  
Qy 207 GNRREBECAFRKLFTRNCFLDGIAQAF 233  
Db 325 GNMEEBECEKELROPTENPCIRNAIQAF 351

---

RESULT 3  
US-10-872-161-40  
; Sequence 40, Application US/10872161  
; Publication No. US20040235714A1  
; GENERAL INFORMATION:  
; APPLICANT: FOX, GARY M.  
; APPLICANT: JING, SHUQIAN  
; APPLICANT: WEN, DUANZHI  
TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR  
FILE REFERENCE: A-4010  
CURRENT APPLICATION NUMBER: US/10/872,161  
CURRENT FILING DATE: 2004-06-18  
PRIOR APPLICATION NUMBER: US/08/866,354  
PRIOR FILING DATE: 1997-05-30

RESULT 4  
US-09-388-316-6  
; Sequence 6, Application US/09388316  
; Publication No. US20020051972A1  
; GENERAL INFORMATION:  
; APPLICANT: Robert D. Klein, Arnon Rosenthal, Mary A. Hynes  
TITLE OF INVENTION: Neurturin Receptor  
NUMBER OF SEQUENCES: 19  
CORRESPONDENCE ADDRESS:  
ADRESSEER: Genentech, Inc.  
STREET: 1 DNA Way  
CITY: South San Francisco  
STATE: California  
COUNTRY: USA  
ZIP: 94180  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Winpatin (Genentech)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/388,316  
FILING DATE: 01-Sep-1999  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 09/024,665  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 60/049818  
FILING DATE: 9-Jun-1997  
APPLICATION NUMBER: 60/038839  
FILING DATE: 18-Feb-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Torchia, PhD., Timothy E.  
REGISTRATION NUMBER: 36,700  
REFERENCE/DOCKET NUMBER: P1086R3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650/225-8674  
TELEFAX: 650/952-9881



PRIOR APPLICATION NUMBER: 09/024,665  
PRIOR FILING DATE: 1998-02-17  
PRIOR APPLICATION NUMBER: 60/063,258  
PRIOR FILING DATE: 1997-10-24  
PRIOR APPLICATION NUMBER: 60/049,818  
PRIOR FILING DATE: 1997-06-09  
PRIOR APPLICATION NUMBER: 60/038,839  
PRIOR FILING DATE: 1997-02-18  
NUMBER OF SEQ ID NOS: 30  
SOFTWARE: FastSEQ for Windows Version 4.0  
SEQ ID NO 18  
LENGTH: 664  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: This sequence is a fusion protein comprising rat  
OTHER INFORMATION: NTNRAalpha sequence and human FC sequence.  
US-10-357-822-18

RESULT 10 ; APPLICANT: Zhang/Zemin  
 US-10-872-972-62 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND  
 ; Sequence 62, Application US/10872972 ; FILE REFERENCE: P5010R1-US  
 ; Publication No. US20040229277A1 ; CURRENT APPLICATION NUMBER: US/10/872,991  
 ; GENERAL INFORMATION: ; CURRENT FILING DATE: 2004-05-21  
 ; APPLICANT: Frantz,Gretchen ; PRIOR APPLICATION NUMBER: US/10/241,220  
 ; APPLICANT: Hillian,Kenneth J. ; PRIOR FILING DATE: 2002-09-11  
 ; APPLICANT: Phillips,Heidi ; NUMBER OF SEQ ID NOS: 120  
 ; APPLICANT: Polakis,Paul ; SEQ ID NO: 62 ; LENGTH: 460  
 ; APPLICANT: Spencer,Susan ; TYPE: PRT ; ORGANISM: Homo Sapien  
 ; APPLICANT: Wu,Thomas ; LENGTH: 460  
 ; ORGANISM: Homo Sapien

RESULT 11 ; APPLICANT: Zhang/Zemin  
 US-10-872-972-62 ; TITLE OF INVENTION: TREATMENT OF TUMOR  
 ; Sequence 62, Application US/10872972 ; FILE REFERENCE: P5010R1-US  
 ; Publication No. US20040229277A1 ; CURRENT APPLICATION NUMBER: US/10/872,991  
 ; GENERAL INFORMATION: ; CURRENT FILING DATE: 2004-05-21  
 ; APPLICANT: Frantz,Gretchen ; PRIOR APPLICATION NUMBER: US/10/241,220  
 ; APPLICANT: Hillian,Kenneth J. ; PRIOR FILING DATE: 2002-09-11  
 ; APPLICANT: Phillips,Heidi ; NUMBER OF SEQ ID NOS: 120  
 ; APPLICANT: Polakis,Paul ; SEQ ID NO: 62 ; LENGTH: 460  
 ; APPLICANT: Spencer,Susan ; TYPE: PRT ; ORGANISM: Homo Sapien  
 ; APPLICANT: Wu,Thomas ; LENGTH: 460  
 ; ORGANISM: Homo Sapien

RESULT 12 ; APPLICANT: WEN, Duanzhi  
 US-10-155-693-10 ; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR  
 ; Sequence 10, Application US/10155693 ; FILE REFERENCE: A-401C  
 ; Publication No. US20030175876A1 ; CURRENT APPLICATION NUMBER: US/10/155,693  
 ; GENERAL INFORMATION: ; CURRENT FILING DATE: 2002-05-24  
 ; APPLICANT: FOX, GARY M. ; PRIOR APPLICATION NUMBER: US/08/837,199  
 ; APPLICANT: JING, SHUQIAN ; PRIOR FILING DATE: 1997-04-14  
 ; APPLICANT: KGNCLDAKACNMLDDICKKKYRSAYITPCTSV--SNDVCRKCKHAKRQFDKVKPAK ; PRIOR APPLICATION NUMBER: US/60/015,907  
 ; APPLICANT: LTHALLFGCGCAGCAERRQTAPACAFGSPOLAPSCPLKPLDRCRSRCRPRFLAQ ; PRIOR FILING DATE: 1996-04-22  
 ; APPLICANT: HSYGMLFCSCRDIATERRTQIVPVSYE--EREKNCLNQDSCKTNYIERSLADPP ; PRIOR APPLICATION NUMBER: US/60/017,221  
 ; APPLICANT: 153 ASCAPARGSRDGCPEEGPRCLRAYAGSLVGTWTPNTLDNNSARVAPWCGCERASGRREE ; PRIOR FILING DATE: 1996-05-09  
 ; APPLICANT: 260 TNQPESRSSRSRDLGTAQAFSSQPSVLQDQNP ; NUMBER OF SEQ ID NOS: 47  
 ; APPLICANT: 213 CEAFLKLFTRNPCLDGAQAFSSQPSVLQDQNP ; SOFTWARE: Patentin version 3.1  
 ; APPLICANT: 320 CLKFLNFFKDNTCLKNAIQAFGNGSDVT--WQP ; SEQ ID NO: 10 ; LENGTH: 463  
 ; APPLICANT: ; TYPE: PRT ; ORGANISM: HUMAN  
 ; FEATURES: ; FEATURES:  
 ; NAME/KEY: misc\_feature ; NAME/KEY: misc\_feature  
 ; LOCATION: (5)-(5) ; LOCATION: (5)-(5)  
 ; OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser. ; OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser.  
 ; GENERAL INFORMATION: ; FEATURES:  
 ; APPLICANT: Frantz,Gretchen ; NAME/KEY: misc\_feature  
 ; APPLICANT: Hillian,Kenneth J. ; LOCATION: (1)-(537)  
 ; APPLICANT: Phillips,Heidi ; OTHER INFORMATION: No. US20030175876A1= "1 to 537 is -235 to 301 of Figure 5 diacon  
 ; APPLICANT: Polakis,Paul ; FEATURES:  
 ; APPLICANT: Spencer,Susan ; NAME/KEY: misc\_feature  
 ; APPLICANT: Williams,P.Mickey ; LOCATION: (550)-(550)  
 ; APPLICANT: Wu,Thomas ; OTHER INFORMATION: N in position 550 indicates any nucleic acid  
 ; APPLICANT: ; OTHER INFORMATION: N in position 550 indicates any nucleic acid

RESULT 11 ; APPLICANT: WEN, Duanzhi  
 US-10-872-991-62 ; TITLE OF INVENTION: TREATMENT OF TUMOR  
 ; Sequence 62, Application US/10872991 ; FILE REFERENCE: P5010R1-US  
 ; Publication No. US20040229277A1 ; CURRENT APPLICATION NUMBER: US/10/872,991  
 ; GENERAL INFORMATION: ; CURRENT FILING DATE: 2004-05-21  
 ; APPLICANT: Frantz,Gretchen ; PRIOR APPLICATION NUMBER: US/10/241,220  
 ; APPLICANT: Hillian,Kenneth J. ; PRIOR FILING DATE: 2002-09-11  
 ; APPLICANT: Phillips,Heidi ; NUMBER OF SEQ ID NOS: 120  
 ; APPLICANT: Polakis,Paul ; SEQ ID NO: 62 ; LENGTH: 460  
 ; APPLICANT: Spencer,Susan ; TYPE: PRT ; ORGANISM: Homo Sapien  
 ; APPLICANT: Wu,Thomas ; LENGTH: 460  
 ; ORGANISM: Homo Sapien

RESULT 12 ; APPLICANT: WEN, Duanzhi  
 US-10-155-693-10 ; TITLE OF INVENTION: GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTOR  
 ; Sequence 10, Application US/10155693 ; FILE REFERENCE: A-401C  
 ; Publication No. US20030175876A1 ; CURRENT APPLICATION NUMBER: US/10/155,693  
 ; GENERAL INFORMATION: ; CURRENT FILING DATE: 2002-05-24  
 ; APPLICANT: FOX, GARY M. ; PRIOR APPLICATION NUMBER: US/08/837,199  
 ; APPLICANT: JING, SHUQIAN ; PRIOR FILING DATE: 1997-04-14  
 ; APPLICANT: KGNCLDAKACNMLDDICKKKYRSAYITPCTSV--SNDVCRKCKHAKRQFDKVKPAK ; PRIOR APPLICATION NUMBER: US/60/015,907  
 ; APPLICANT: LTHALLFGCGCAGCAERRQTAPACAFGSPOLAPSCPLKPLDRCRSRCRPRFLAQ ; PRIOR FILING DATE: 1996-04-22  
 ; APPLICANT: HSYGMLFCSCRDIATERRTQIVPVSYE--EREKNCLNQDSCKTNYIERSLADPP ; PRIOR APPLICATION NUMBER: US/60/017,221  
 ; APPLICANT: 153 ASCAPARGSRDGCPEEGPRCLRAYAGSLVGTWTPNTLDNNSARVAPWCGCERASGRREE ; PRIOR FILING DATE: 1996-05-09  
 ; APPLICANT: 260 TNQPESRSSRSRDLGTAQAFSSQPSVLQDQNP ; NUMBER OF SEQ ID NOS: 47  
 ; APPLICANT: 213 CEAFLKLFTRNPCLDGAQAFSSQPSVLQDQNP ; SOFTWARE: Patentin version 3.1  
 ; APPLICANT: 320 CLKFLNFFKDNTCLKNAIQAFGNGSDVT--WQP ; SEQ ID NO: 10 ; LENGTH: 463  
 ; APPLICANT: ; TYPE: PRT ; ORGANISM: HUMAN  
 ; FEATURES: ; FEATURES:  
 ; NAME/KEY: misc\_feature ; NAME/KEY: misc\_feature  
 ; LOCATION: (5)-(5) ; LOCATION: (5)-(5)  
 ; OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser. ; OTHER INFORMATION: The 'xaa' at location 5 stands for Thr, Ala, Pro, or Ser.  
 ; GENERAL INFORMATION: ; FEATURES:  
 ; APPLICANT: Frantz,Gretchen ; NAME/KEY: misc\_feature  
 ; APPLICANT: Hillian,Kenneth J. ; LOCATION: (1)-(537)  
 ; APPLICANT: Phillips,Heidi ; OTHER INFORMATION: No. US20030175876A1= "1 to 537 is -235 to 301 of Figure 5 diacon  
 ; APPLICANT: Polakis,Paul ; FEATURES:  
 ; APPLICANT: Spencer,Susan ; NAME/KEY: misc\_feature  
 ; APPLICANT: Williams,P.Mickey ; LOCATION: (550)-(550)  
 ; APPLICANT: Wu,Thomas ; OTHER INFORMATION: N in position 550 indicates any nucleic acid  
 ; APPLICANT: ; OTHER INFORMATION: N in position 550 indicates any nucleic acid



; NUMBER OF SEQ ID NOS: 61  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO: 1  
; LENGTH: 463  
; TYPE: PRT  
; ORGANISM: HUMAN  
US-10-872-161-12

Query Match 32.9%; Score 465; DB 17; Length 463;  
Best Local Similarity 41.9%; Pred. No. 7.8e-32;  
Matches 90; Conservative 30; Mismatches 87; Indels 8; Gaps 3;  
Oy 33 EGSRCVVEAECTADEQCOQLRSBYVAOCLGRAGWRGPSCYVSRCCRALLRREFARGPPA 92  
Db 150 KGNICLDAKACIUDICKKKRSAYITCTSV--SNDVCNRRKCHKALRQFDKYPAK 206  
Oy 93 LTHALLFCGGCEGACASERRQTAPACAFSGPQLAPPSCLLPKUDCRCSRERPRPAFO 152  
Db 207 HSTGMILFSCRDIACTERRRQTIVPVSYE--BREKENCLNLQDSCKNYICKSRILADPF 264  
Oy 153 ASCAPAPCPSRDRGPEEGPRCURAYAGIVGTUTPNYLNVNSARAVAPMCGEASGNRRE 212  
Db 265 TNQPESRSSVSLKENYADCLLAYSGLIGTWTNPYIDSSLSVABWCDCCNSGLEE 324  
Oy 213 CEAFLRKLTTRNPCLDGA1QAFDSSQPSVLQDQNP 247  
Db 325 CLKFLNFFKDNTCLKNA1QAFGNGSDVTV--WQP 356

Search completed: January 26, 2005, 13:28:26  
Job time : 149 sec

